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resumo 
 
 
A Monitorização Ambulatória da Pressão Arterial (MAPA) tem valor preditor de 
eventos cardiovasculares em doentes sem evento prévio. No entanto, o valor 
preditor para eventos secundários não foi ainda estabelecido na comunidade 
médica. 
Neste trabalho, investigamos o valor preditivo da MAPA em doentes com evento 
cardiovascular prévio, considerando as variáveis seguintes: pressão arterial 
(PA) de 24 horas, diurna e noturna, queda noturna, pressão de pulso diurno e 
noturno e frequência cardíaca.  
Realizámos um estudo observacional numa população de adultos com evento 
cardiovascular prévio, referenciado para MAPA entre 1996 e 2017 no Centro 
Hospitalar do Baixo Vouga. Foram avaliados um total de 391 registos de MAPA 
de 295 doentes hipertensos, dos quais 72.6% eram homens, 37.6% eram 
diabéticos e 19.2% eram fumadores. Os eventos cardiovasculares prévios 
incluíram: 235 eventos coronários, 140 acidentes vasculares cerebrais 
isquémicos, 11 acidentes vasculares cerebrais hemorrágicos e cinco cirurgias 
vasculares carotídeas e periféricas. Durante um follow-up de 4.5 ± 5.2 anos, 
foram observados 93 eventos recorrentes, dos quais 42 acidentes vasculares 
cerebrais isquémicos, 38 eventos coronários, sete acidentes vasculares 
hemorrágicos, cinco cirurgias arteriais periféricas e uma endarterectomia 
carotídea. 
O estudo permitiu concluir que: (1) a MAPA teve valor preditivo para eventos 
cardiovasculares recorrentes em doentes com evento cardiovascular prévio; (2) 
de entre os valores da MAPA, o valor preditivo dos valores sistólicos e 
diastólicos diurnos foram superiores aos de 24 horas, e que os valores noturnos 
não têm valor preditivo para eventos cardiovasculares recorrentes; (3) os limites 
da MAPA para predição de eventos recorrentes foram mais baixos que os 
usados para predição primária (4) ; a MAPA teve um valor preditivo de eventos 
recorrentes superior nos doentes < 65 anos relativamente aos doentes ≥ 65 anos 
e em doentes com < 65 anos, o valor preditivo dos valores sistólicos (24 horas, 
diurnos e noturnos) foi superior ao dos respetivos valores diastólicos; (5) os 
valores da MAPA antes do evento para depois do evento diminuem na sua 
globalidade. 
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abstract 
 
Ambulatory blood pressure monitoring (ABPM) is a predictor of cardiovascular 
outcomes in patients without previous cardiovascular events. However, the same 
predictive value for secondary events is not yet established in the medical 
community. 
In this work, we investigate the predictive value of ABPM for patients with prior 
cardiovascular events, considering the following variables: 24-hour blood 
pressure (BP), daytime and night-time BP, BP dipping, daytime and night-time 
pulse pressure and heart rate.  
We conducted an observational study on a population of adults with previous 
cardiovascular events, referenced for ABPM between 1996 and 2017 at Centro 
Hospitalar do Baixo Vouga. A total of 391 ABPM records from 295 hypertensive 
patients, from which 72.6% were men and 37.6% were diabetic, were evaluated. 
Previous cardiovascular events included 235 coronary events, 140 ischemic 
strokes, 11 hemorrhagic strokes and five carotid and peripheral artery surgeries. 
During a mean follow-up of 4.5 ± 5.2 years, 93 recurrent cardiovascular events 
were observed, namely 42 ischemic strokes, 38 coronary events, seven 
hemorrhagic strokes, five peripheral artery surgeries and one carotid 
endarterectomy. 
The present work allowed us to conclude that (1) ABPM has predictive value for 
recurrent cardiovascular events in patients with previous cardiovascular events; 
(2) the predictive value of systolic and diastolic blood pressure values obtained 
from ABPM were superior to the 24 hour, and that night-time has no predictive 
value for recurrent events; (3) ABPM thresholds that predict the second event 
are lower than those used for predicting first events; (4) ABPM has a stronger 
prediction value for recurrent events in patients < 65 years when comparing to 
patients ≥ 65 years old; in patients with < 65 years old, the predictive value of the 
systolic blood pressure values (24h, daytime and night-time) was superior to the 
respective diastolic values; (5) ABPM values from before the event and after the 
event decrease overall. 
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1 Introduction 
1.1 Context and motivation 
The population of cardiovascular (CV) event survivors is increasing. More than 85 million patients alive 
in Europe  in 2015 (see Figure 1) and over 92 million in the United States (2011-2014) have established 
CV disease (1)(2). In developing countries, it is becoming a major public health problem (3).  
 
Figure 1 - Age-standardised disability-adjusted life years rate for stroke, 2015, Europe (from: European Cardiovascular 
Disease Statistics. 2017 edition. European Heart Network) 
The high prevalence of CV disease requires a major effort in treatment and prevention of recurrent 
events. The enhancement of secondary risk stratification may provide guidance for better allocation 
of resources to patients at true high risk, and to prevent patients with lower risk from intensive 
therapy side effects and rigorous surveillance. 
Currently, the risk stratification strategies recommended for recurrent events and proper validated 
are directed to the short-term. Significant predictors  and consensual prediction models of recurrent 
events for stable and established CV disease are still lacking (4)(5). The clinical practice would benefit 
from the availability of an accurate and validated prediction tool with reliable predictors to better 
stratify patients with established CV disease. 
The gap concerning blood pressure use in recurrent event prediction 
Blood pressure (BP) is a known CV risk factor and one of the most powerful predictors of events in 
primary prediction. The role of BP in the prediction of recurrent CV events is still uncertain. There is 
discrepancy in literature concerning BP as a solid predictor of second event. Most studies use the 
diagnosis of hypertension or the measurement of BP at baseline as candidate predictor. Ambulatory 
blood pressure monitoring (ABPM) provides more amount of information and is a stronger predictor 
of events than office BP in primary prediction. There is little knowledge concerning the value of ABPM 
in secondary prediction (6). 
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1.2 Previous work at CHBV and new contributions  
The “Cardiovascular prognostic value of ambulatory monitoring in a Portuguese hypertensive 
population” study was developed from 1991 to 1998 and followed a cohort of 1200 patient without 
previous CV disease and referred for ABPM for 8.9 years (7)(8)(9). This study was developed in Centro 
Hospitalar do Baixo Vouga and Hospital Pedro Hispano and was the first study of a Portuguese 
hypertensive population to evaluate the prognostic value of ABPM for total CV, stroke and coronary 
events. The study was able to show the higher predictive value of ABPM comparing with office BP for 
first CV event. This project led to the question if ABPM was also superior to office BP in the prediction 
of recurrent CV events. 
In connection to the results attained in the project, we faced the question whether ABPM would also 
have value in the prediction of recurrent CV events.  This question motivated and is the corner-stone 
of the present work. 
The patients with CV event in the prior cohort were selected and shaped the initial population sample 
for the work we present here; other patients were included to extend the cohort, considering the 
information in clinical records up to 2018. 
1.3 Research questions 
The aim of this work is to study the value of ABPM and its variables in the prediction of recurrent CV 
events for a population with established CV disease, selected from regular clinical practice at an acute 
care hospital. The main proposed contributions were to ascertain the possible role of ABPM in the 
secondary prediction and to demonstrate the benefit of ABPM for the stratification of risk of patients 
with previous event. 
The five research questions that led the present work were the following: 
1. Does ABPM have any predictive value for recurrent cardiovascular disease? 
2. Which ABPM variables have the highest predictive value for recurrent cardiovascular events, 
if any? 
3. Will the limits of BP that best predict the first CV events be identical to those that predict the 
second events? 
4. ABPM prediction values for recurrent cardiovascular events are they different between 
distinct age groups?  
5. How far and how much ABPM data change from before through after the event?  
1.4 Thesis structure 
The present text is structured as follows: 
• Chapter 1 introduces the present work, the research goals and existing context. 
• In chapter 2, 3 and 4 we review the background concepts and the state of the art, focusing on 
secondary prediction, the development of prediction scores and the characteristics of its 
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variables, the role of blood pressure in secondary event long-term prediction and a literature 
review concerning the predictive value of ABPM in primary and secondary prediction. 
• In chapter 5, we describe the Methods, reporting in detail the methodology and statistical 
analysis used in the present work. 
• In chapter 6, we present the results, structured according to the research questions. 
• In chapter 7, we offer a critical appraisal of the results, comparing and relating to the 
published literature, and giving potential explanations for some findings. 
• In chapter 8, we summarize our main findings and propose new research directions.  
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2 Secondary prediction of cardiovascular events: literature 
review 
2.1 Introduction 
CV disease is a major public health issue. In Europe there were over 5,700,000 new cases of ischemic 
heart disease and over 1,500,000 new strokes during 2015 (10). In United States there 580,000 new 
and 210,000 recurrent myocardial infarction (2), and 610,000 new and 185,000 recurrent strokes (2).  
Patients who survived CV events have different recurrent event risk. The stratification of these 
patients could identify those who would most benefit from aggressive risk factor modification, stricter 
surveillance and individualized optimal treatment (11) (12) (13).  
These patients need continued effective and long-term care (14), tight surveillance, and lifelong 
periodical exams, consultations and medication. This burden raises the costs with treatment, 
prevention, rehabilitation, novel medications and follow-up. Additional costs come also from 
disability, work absence, lack of productivity and quality of life, highlighting the relevance of CV 
disease in terms of public health decisions (15).  
Prediction of CV events allows the recognition of the individuals most at risk and the focus on 
preventive measures to avoid or delay the onset of a new event (16). According to current 
international guidelines (17) (18) and most commonly used prediction scores (19) (20) (21), the 
survivors of a CV event have the highest CV risk, but it is the same level of risk for all these patients. If 
so, this means they will all benefit equally of the same treatment. However, physicians intuitively feel 
this is not accurate (15) and their heterogeneous risk spectrum is nowadays recognized (22). 
Choices like intense platelet inhibition (23), highly expensive treatments as proprotein convertase 
subtilisin/kexin type 9 (PCSK9) inhibitors (24) or implantable cardioverter-defibrillator therapy (25) 
could benefit some patients, while others need a more conservative approach with obvious reduction 
in side effects. Intensive therapy side effects such as hypotension, bleeding, rhabdomyolysis or cardiac 
rhythm disturbances, may be avoided by a better stratification (26). Other important reasons are the 
patient personal need for information on his health and risk status (15), motivation to lifestyle changes 
and medication compliance(17), and an enhanced randomisation for future clinical trials (27)(28).  
Several cohorts with established CV disease have and are being studied. The REACH (REduction of 
Atherothrombosis for Continued Health) registry is an international project started in 2003, of patients 
with established vascular disease and/or at least three atherothrombotic risk factors (29). The SMART 
cohort (30) includes patients with  clinically manifest atherosclerotic disease and the Framingham 
registry (31) has a secondary event subpopulation. 
The identification of features that enables the occurrence of events allows the development of models 
and algorithms (19,21,32–35) that calculate the probability of an event in a given period of time (36). 
For long term prediction, single variables usually do not allow good accuracy for the individual, and 
multivariate models are required (37). 
Several entangled issues influence the development and performance of recurrent CV risk scores, 
becoming a highly complex area. 
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We present an overview of CV secondary prediction models developed for long term (≥ 3 years), and 
elaborate on their development, validation and implementation. 
2.2 Methods  
A literature search was performed on the Medline database for studies which developed multivariate 
(minimum 2 or more variables) prediction models for long-term (≥ 3 years) CV events or mortality in 
patients with previous CV disease. The later was defined as previously diagnosed angina pectoris, 
myocardial infarction, previous percutaneous coronary intervention (PCI) or coronary artery bypass 
grafting (CABG), stroke or transient ischaemic attack, diagnosed peripheral artery disease (PAD), or 
carotid atherosclerosis. Models predicting outcome for specific subgroups (i.e. selected populations 
with specific comorbidities or submitted to specific procedures) which do not reflect the broader CV 
disease population were excluded. Models developed to a specific decision making (use or not of 
certain drug or procedure, for example) were not considered. Only studies which examined one or 
more of the following endpoints were selected: mortality (total or CV), sudden death, CV event or 
combinations of any of these. The search was limited to studies written in English.  
The literature search was performed on 4th September 2017, using a combination of key words 
((secondary OR recurrent) AND (score* OR model) AND (cardiovascular OR cardiac OR vascular OR 
atherosclerosis) AND predict*) and free text. From a total of 3285 articles, 55 articles were selected 
by title and abstract. From these, 18 articles matched the inclusion parameters. By further exploring 
the refence lists and citations, another 22 articles were identified and selected. A total of 40 papers 
fulfilled the inclusion criteria.  
The following data were retrieved from each paper: description of the underlying objectives, aspects 
of the developed prediction model including inclusion and exclusion criteria, cohort features, number 
of events, outcome definition, risk predictor selection, missing data, model-building strategies and 
performance variables were collected. The CHecklist for critical Appraisal and data extraction for 
systematic Reviews of prediction Modelling Studies (CHARMS) was used to guide data recollection 
(38).  
Moreover, reviews, editorials, and several articles were reviewed, through reference lists, citations 
and free search, and issues and features concerning secondary CV prediction were compiled and 
addressed. 
2.3 Results  
The 55 references identified were read in full: 18 were selected and 37 were excluded (Figure 2). 
Additional 22 articles were selected through reference lists and manual searches. 
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Figure 2 - Selection of articles 
 
A total of 40 references was selected, describing 56 models. Five of these models had more than one 
type of presentation (e.g. mathematical equation, risk chart, sum score) (Table 1). The populations 
selected in each article had different primary vascular events: 26 studies evaluated patients with 
coronary disease (14 with acute coronary syndrome, 12 with established coronary heart disease), 
seven studies evaluated patients with atherosclerotic disease in different vascular beds, one study 
evaluated patients with atherosclerotic disease or diabetes (even without CV event), three evaluated 
patients with stroke, one study evaluated patients with stroke and coronary heart disease, one study 
evaluated patients with CV disease (no definition of CV disease was given) and one study evaluated 
patients with PAD. The definition of established CV disease was different between studies (seven 
included only patients with acute myocardial infarction, seven included patients with acute coronary 
syndrome (ACS) including unstable angina, seven included patients with atherosclerotic disease, and 
one included patients with established atherosclerotic event or diabetes). Nine studies addressed the 
validation of former models: four for coronary disease patients (39)(40)(41)(42), three for stroke 
populations (43)(44)(45) and two for atherosclerotic disease patients (46)(47). Of the nine, five were 
for validation for longer term of a score previously developed for shorter term (39) (40)(41)(42) (43), 
one was for validation of a specific risk class of guidelines (47), one for validation of scores previously 
validated for the primary event population (46), one for validation of a diagnosis score for long term 
prognosis (45), one studied two different scores (one developed previously for primary event with 
patients with a specific comorbidity; another short term secondary prediction score) and evaluated 
their performance for secondary event long term prediction in patients (44). Some studies made 
adaptations from previous known and validated scores (48)(49)(50). Three studies developed a score 
with external validation (51)(4)(52) and from the 28 developing studies, 17 presented internal 
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validation (seven by bootstrapping, five by split data, four by cross-validation and one by 
bootstrapping and cross-validation).  
The dates of the studies were different (spanning from 1985 to 2011). 
Population samples were distinct: average age ranges between 57 and 72 years old, male percentage 
between 54,3-86.1%, prior stroke between 2-36%, diabetes between 9-48%, and tobacco disorder 
between 10-82%. 
 
Table 1 – Selected papers with long-term recurrent cardiovascular events scores and key facts 
Name Pop Dev/ 
Val 
Age Study 
dates 
Outcome Time of 
prediction 
Sample 
size 
Int 
val 
Ext 
Val 
Final 
model 
given 
Plakht 2012 
(53) 
AMI Dev * 2002-
2004 
all-cause mortality 5 2772 ✓  ✓ 
Marchioli 
2001 (54) 
AMI Dev 59 1993-
1995 
all-cause mortality 4 11248 ✓  ✓ 
Bohula 2016 
(26) 
CAD Dev 59  CV death, MI, 
ischaemic stroke 
3 8598 ✓  ✓ 
Dorresteijn 
2013 (15) 
Ather D. Dev 60 1996-
2010 
CV death, MI, 
ischaemic or 
haemorrhagic stroke 
7 (10)Ɏ 5788 ✓  ✓ 
Papavasileiou 
2013 (43) 
Isch 
stroke 
Val 72 1998-
2010 
functional outcome 
and mortality 
5 1520   ✓ 
Ganz 2016 
(51) 
CAD Dev 67 2000-
2002 
MI, stroke, heart 
failure, all-cause 
mortality 
4 912  ✓ ✓ 
Beatty 2015 
(4) 
CAD Dev  2000-
2002 
composite (time to 
first nonfatal MI, 
stroke, CV death) 
5 912 ✓ ✓  
Battes 2013 
(55) 
CAD Dev 60 1997-
2000 
single: MI, CABG, PCI, 
non-CV death; 
composite 1 (CV death, 
nonfatal MI, 
resuscitated cardiac 
arrest), composite 2 
(CV death, non-CV 
death, MI, CABG, PCI, 
resuscitated cardiac 
arrest) 
4 12218 ✓   
Kleber 2014 
(56) 
CAD Dev 65 1997-
2000 
all-cause mortality 10 1275 ✓  ✓ 
Goliasch 2012 
(52) 
CAD Dev 64 1999-
2000 
all-cause mortality 10 547 ✓ ✓ ✓ 
Tang 2007 
(39) 
ACS Val 64.9 2000-
2002 
all-cause mortality 4 1057   ✓ 
Fox 2014 (48) ACS Dev *  all-cause mortality 3 1274  ✓ ✓ 
Marschner 
2001 (57) 
ACS Dev 62 1989 CAD death or nonfatal 
MI 
5 8557 ✓  ✓ 
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Name Pop Dev/ 
Val 
Age Study 
dates 
Outcome Time of 
prediction 
Sample 
size 
Int 
val 
Ext 
Val 
Final 
model 
given 
Sprengers 
2009 (58) 
PAD Dev 58 1996-
2007 
CV death, MI, 
ischaemic or 
haemorrhagic stroke 
5 800 ✓  ✓ 
Ingle 2013 
(49) 
CVD Dev 66.4 1998-
2004 
CV death ** 1372    
Tragante 
2013 (59) 
Ather D. Dev 60.6 1996-
2007 
all CV events / MI ** 8446    
De Bacquer 
2013 (60) 
CAD Dev * 1995- 
1996 
all-cause mortality 5 5216   ✓ 
Uthoff 2010 
(46) 
Ather D. Val 67.7 1999-
2000 
SMART: CV death, MI, 
ischaemic or 
haemorrhagic stroke; 
PROCAM: CAD; 
FRAMINGHAM: 
developing coronary 
death, MI, angina 
pectoris or coronary 
insufficiency; SCORE: 
CV death 
6 96    
Van den Berg 
2017 (47) 
Ather D. Val 60.1 1996-
2004 
CV death, MI, 
ischaemic or 
haemorrhagic stroke 
10 SMART- 
7216; 
REACH – 
48322 
   
Deckers 2006 
(61) 
CAD Dev 60 1997 
– 
2000 
Composite (CV death, 
MI, resuscitated 
cardiac arrest) 
10 12218   ✓ 
Rizza 2015 
(50) 
Ather D. Dev * 2005 nonfatal stroke, 
nonfatal MI, peripheral 
vascular surgery 
4 298   ✓ 
Andersen 
2015 (44) 
Stroke Val * 2003-
2012 
stroke, death, CV 
events 
5 42182    
Lau 2017 (45) Stroke Val * 2004-
2014 
stroke, ischaemic 
stroke, intracerebral 
haemorrhage 
** 2002  ✓  
Blankenberg 
2006 (62)  
Ather D 
and 
diabetics 
Dev * 1993 MI (fatal and nonfatal), 
stroke, CV death 
** 3199    
Mega 2015 
(63) 
AMI Dev * ** CAD ** CARE: 
2878 / 
PROVE-
IT – 
1999 
  ✓ 
Vaara 2016 
(64) 
ACS Dev 66.8 2006 single: recurrent ACS; 
composite: CAD death, 
ACS 
5 2090   ✓ 
Wassink 2011 
(65) 
Ather D. Dev 59 1996 any CV event (CV 
death, ischaemic 
stroke, MI) 
3 3679    
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Name Pop Dev/ 
Val 
Age Study 
dates 
Outcome Time of 
prediction 
Sample 
size 
Int 
val 
Ext 
Val 
Final 
model 
given 
D’Agostino 
1998 (31) 
CAD and 
stroke 
Dev * 1968 single: CAD events (MI, 
angina pectoris, 
coronary insufficiency, 
sudden CAD death, 
non-sudden CAD 
death); composite 
4 1176   ✓ 
Plakht 2015 
(66) 
AMI Dev 66.6 2002 all-cause mortality 10 2763    
Clayton 2005 
(67) 
ACS Dev * 1996 death, MI, disabling 
stroke 
5 7311 ✓  ✓ 
Chen 2016 
(68) 
CAD Dev 63.6 2008 all-cause and CV 
mortality 
4 1911 ✓  ✓ 
Atwater 2009 
(69) 
CAD Dev * 1985 sudden cardiac death 10 37258 ✓ ✓ ✓ 
Hsia 2008 (70) CAD Dev 64 2000 sudden cardiac death 4 8290 ✓  ✓ 
Cui 2009 (71) ACS Dev 63 1990 CVD event (MI, stroke, 
CVD-related death), 
follow-up 
5 55654 ✓  ✓ 
Rapsomaniki 
2013 (72) 
CAD Dev 68.9 2000 all-cause mortality; 
composite (non-fatal 
MI or coronary death) 
5 102023 ✓ ✓ ✓ 
Plankht 2012 
(42) 
AMI Val * 2002 all-cause mortality 10 2772   ✓ 
Fox 2010 (40) ACS Val 66 1999 all-cause mortality and 
MI 
5 3721    
Cui 2010 (73) AMI Dev ** 1990 recurrence of MI event 
and the time from 
randomisation to MI 
event 
** 8557    
Truong 2009 
(41)  
AMI Val 57 1986 death, recurrent MI, 
CHF, composite (death 
or recurrent MI), 
composite  
(death or CHF) 
3 3153    
van Peet 2013 
(74) 
Ather D. Dev 85 1997 CV morbidity and CV 
mortality composite 
(incident fatal and non-
fatal MI, incident fatal 
and non-fatal stroke or 
any other CV mortality) 
5 282 ✓  ✓ 
* characteristics not given for the total of the population 
** not specified 
Ɏ models fitted for 7 years and extrapolated for 10 years 
ACS – Acute coronary syndrome; AMI – acute myocardial infarction; Ather – Atherosclerotic; CABG – coronary artery bypass grafting; CAD – 
coronary artery disease; CV – cardiovascular; CVD – Cardiovascular Disease; D. – Disease; Dev – Development; MI – myocardial infarction; 
PAD – Peripheral artery disease; PCI – percutaneous coronary intervention; Val- Validation 
 
Concerning developing scores, eleven studies were based in randomised trials populations, with 
subsequent stricter inclusion and exclusion criteria, and twenty from cohorts. The time enrolment in 
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relation to the first event  was different among studies: five studies enrolled patients at discharge, one 
enrolled within three months after the event, one after two and one after four weeks, seven after 
three months, four after six, one study did not present defined criteria for time of enrolment (from 
acute event to many years after) and one study had two cohorts with different time of enrolment. 
Nine studies did not provide objective information or reference to previous description about time for 
enrolment after the event (two of these were community-based samples). Seven studies had age 
restriction, six studies excluded patients with heart failure or renal impairment, six excluded patients 
with unfavourable short-term prognosis or terminal malignancy, three used place of residence or 
willing to move away as exclusion criteria, two excluded patients with hepatic disease, one had no 
exclusion criteria. Ten studies had no reference to exclusion criteria. Inclusion criteria of patients were 
different between studies, and even some definitions also differed. Inclusion criteria of angiographic 
evidence of coronary artery disease (CAD) varied between 50% to 75% stenosis. Some studies included 
patients without proven event if they had evidence of ischaemia in stress tests (five studies), 
electrocardiogram (ECG) changes consistent with ACS (one study) or diabetes (one study). Twelve 
studies were based on one centre population, and 19 were multicentre. Most studies (90,3%) did not 
mention patients lost for follow-up, and 35,5% did not address missing data. From those who did, 65% 
of them excluded patients with missing data from analysis. Sample size ranged from a minimum of 
282 patients to a maximum of 102 023 (five studies with population samples below 1000 patients, 20 
with population samples between 1000-10000 patients, and five with population sample over 10000 
patients). Follow up ranged from 3 to 11.3 years, and the event per candidate predictor ratio was <10 
in 22.6% of the studies, and over 20 in 58.1%. In three studies there was no sufficient information to 
calculate the ratio. Table 2 presents the candidate versus selected predictors found more frequently. 
Table 2 - Candidate and selected variables for prediction models more frequently found in the reviewed papers 
Variables Candidate (n) Selected (n) 
MedicationɎ 27 4 
Age 24 21 
Tobacco use disorder 24 18 
Diabetes 21 16 
Gender 21 11 
Renal disease (creatinine / eGFR)* 20 (6/8) 15 (5 /3) 
SBP 20 11 
Prior CAD (MI)** 16 (11) 7 (6) 
BMI 16 4 
HDL cholesterol 15 12 
Prior stroke 15 12 
Total cholesterol 15 10 
Hypertension 14 5 
PAD 9 7 
comorbiditiesɎɎ 9 7 
Heart rate 9 5 
12 
Variables Candidate (n) Selected (n) 
DBP 9 3 
Statin/lipid lowering agents 9 2 
History of heart failure 8 4 
hs-CRP 8 3 
LVEF 7 5 
glucose 7 5 
Ethnic group 7 1 
aspirin 7 1 
revascularization 6 5 
Malignant neoplasm 5 3 
LDL cholesterol 5 3 
Leucocytes 5 3 
Triglycerides 5 2 
Diuretics 5 2 
Angina 5 2 
Family history of CV disease 5 1 
NT-proBNP  4 4 
COPD 4 3 
Angina grade 4 3 
History of CABG 4 1 
Intermittent claudication 4 1 
Alcohol or drug addiction 3 2 
Qualifying event 3 2 
Abdominal obesity 3 2 
Moderate to severe mitral regurgitation 3 2 
Atrial fibrillation 3 1 
hypertriglyceridemia 3 1 
Nitrates 3 1 
Angina duration 3 1 
LVH 3 1 
PCI 2 2 
CABG 2 2 
Thrombolysis 2 2 
Plasma sodium 2 2 
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Variables Candidate (n) Selected (n) 
uACR 2 2 
hs-cTnT 2 2 
Severe LV dysfunction 2 2 
Fibrinogen 2 1 
Physical activity 2 1 
Years since first vascular event 2 1 
Nationality / country of residence 2 1 
Homocysteine 2 1 
STEMI 2 1 
Previous angiography 2 1 
No of diseased coronary arteries 2 1 
sVCAM-1 2 1 
sICAM-1 2 1 
Moderate to severe pulmonary hypertension 2 1 
Echo missing 1 1 
Acute LV failure in hospital 1 1 
No premature ventricular beats 1 1 
Arrhythmias 1 1 
Results of exercise stress test 1 1 
cIMT and carotid stenosis 1 1 
Waist-hip ratio 1 1 
AAA 1 1 
Surgery of arterial disease 1 1 
Social deprivation 1 1 
PCI/CABG within 6 months of event 1 1 
Depression / anxiety 1 1 
No lipid lowering therapy 1 1 
Angina each additional drug 1 1 
Angina attack >= 1/week 1 1 
QT interval 1 1 
Non-STEMI 1 1 
Haemoglobin 1 1 
sTNFR1 1 1 
Symptomatic CAD 1 1 
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Variables Candidate (n) Selected (n) 
ST depression 1 1 
Not having in hospital PCI 1 1 
Psychological distress 1 1 
Ɏ Each drug was counted once (except aspirin, diuretics and lipid-lowering agents) (e.g. ACEI or ARB, anti-coagulants, beta-blockers, CCB, 
digitalis) 
ɎɎ Each comorbidity was counted once (neurological disorders, gastrointestinal haemorrhage, anaemia, schizophrenia or psychosis, 
chronic liver disease) (except malignant neoplasm) 
* Total of candidate predictors of renal disease or renal lesion, including those evaluated by level of plasma creatinine and those by eGFR 
(in parenthesis those defined specifically by creatinine or eGFR, included in the total) 
** Total of candidate predictors of established CAD (in parenthesis those defined specifically by previous MI, included in the total) 
AAA – abdominal aortic aneurysm; ACEI – angiotensin converting enzyme inhibitors; ARB – angiotensin receptor blockers; BMI – body mass 
index; CABG – coronary artery bypass grafting; CAD – coronary artery disease; CCB- calcium channel blockers; cIMT – carotid intima-media 
thickness; COPD – chronic obstructive pulmonary disease; CV – cardiovascular; DBP – diastolic blood pressure; eGFR- estimated glomerular 
filtration rate; HDL – high density lipoproteins; hs-cTNT – high sensitive cardiac troponin T; hsCRP – high sensitivity C-reactive protein; LDL 
– low density lipoproteins; LV – left ventricular; LVEF – left ventricular ejection fraction; LVH – left ventricular hypertrophy; MI – myocardial 
infarction; NT-proBNP – N-terminal pro b-type natriuretic peptide; PAD – peripheral arterial disease; PCI – percutaneous coronary 
intervention; SBP – systolic blood pressure; STEMI – ST-segment elevation myocardial infarction; sICAM-1 – soluble intercellular cell 
adhesion molecule 1; sVCAM-1 – soluble vascular cell adhesion molecule 1; sTNFR1 – soluble tumor necrosis factor receptor 1; uACR – 
urine albumin to creatinine ratio 
 
The selected variables for recurrent prediction models in studies with populations with coronary 
artery event or atherosclerotic event are presented in Table 3, divided by outcome.  
Table 3 – Variables selected for recurrent events prediction models by population sample and outcomes 
Population 
sample 
 Outcome: All-cause mortality Outcome: CV death, MI or stroke 
 n (total 
studies) 
9 8 
ACS + AMI + 
coronary heart 
disease 
22 9/22 
Age – 8 
Echocardiographic changes – 6 
Heart rate – 5 
Creatinine – 4 
Gender -3 
Renal disease-3 
Anaemia-3 
COPD-3 
Malignant neoplasm-3 
HTN – 3 
Plasma sodium-2 
Alcohol or drug addiction-2 
Schizophrenia or psychosis -2 
Neurological disorders – 2 
Diabetes-2 
HDL cholesterol – 2 
3/22 
Age – 3 
Smoking – 3 
Diabetes – 3 
Previous stroke – 3 
Gender – 2 
Ejection fraction – 1 
Leucocytes – 1 
Glucose – 1 
Creatinine – 1 
Angina attack ≥ 1/week – 1 
Previous angiography – 1 
No lipid lowering drugs -1 
QT interval – 1 
SBP – 1 
Each drug for angina – 1 
Previous MI – 1 
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Population 
sample 
 Outcome: All-cause mortality Outcome: CV death, MI or stroke 
Leucocytes -2 
Fasting glucose -2 
PAD – 2 
HgA1c – 2 
Smoking – 2 
CABG-1 
PCI and/or thrombolysis-1 
Obesity-1 
GI haemorrhage-1 
Electrical instability-1 
Residual myocardial ischaemia-1 
Intermittent claudication – post-MI smokers –1 
Fibrinogen -1 
ST deviation – 1 
SBP – 1 
Killip class – 1 
Cardiac arrest at admission – 1 
Biomarkers of necrosis – 1 
Diabetes without renal or peripheral circulation 
changes – 1 
NT-proBNP – 1 
Cystatin C – 1 
Renin – 1 
25OH-vitD3 – 1 
Deprivation – 1 
ACS subtype – 1 
Recent revascularizations – 1 
Previous MI – 1 
Use of long acting nitrates – 1 
Lipids – 1 
Heart failure – 1 
Atrial fibrillation – 1 
Stroke – 1 
Chronic liver disease – 1 
Depression – 1 
Anxiety – 1 
Serum cholinesterase -1 
HTN – 1 
CHF – 1 
Prior CABG, PAD or other 
vascular disease – 1 
eGFR - 1 
16 
Population 
sample 
 Outcome: All-cause mortality Outcome: CV death, MI or stroke 
Total cholesterol -1 
LDL cholesterol - 1 
Atherosclerotic 
disease 
6 0/6 4/6 
Gender – 4 
Age – 3 
Diabetes – 3 
Smoking – 3 
HDL cholesterol – 3 
SBP – 2 
Total cholesterol – 2 
hsCRP – 2 
previous CAD, CVD, PAD or AAA – 
2 
Fasting glucose - 2 
Triglycerides – 2 
proBNP – 2 
HTN – 2 
yrs since 1st vascular event – 1 
eGFR – 1 
cIMT – 1 
presence of carotid stenosis – 1 
Ramipril – 1 
Waist-hip ratio – 1 
LDL/HDL cholesterol – 1 
Lipid lowering drugs – 1 
Microalbuminuria – 1 
Creatinine – 1 
Waist circumference – 1 
Prior MI, stroke or arterial 
surgery – 1 
MDRD – 1 
Homocysteine – 1 
AAA – abdominal aortic aneurysm;  ACS – acute coronary syndrome; AMI – acute myocardial infarction; CABG - coronary artery bypass 
grafting; CAD – coronary artery disease; cIMT – carotid intima-media thickness;   CHF – chronic heart failure;  COPD – chronic obstructive 
pulmonary disease; CV – cardiovascular; CVD – cardiovascular disease; eGFR – estimated glomerular filtration rate; GI – gastrointestinal;  
HgA1c – Haemoglobin A1c; hsCRP – high sensitivity C reactive protein;  HTN – hypertension;  SBP – systolic blood pressure; MDRD – 
Modification of Diet Renal Disease equation; MI – myocardial infarction;  NT-proBNP – N-terminal pro b-type natriuretic peptide;  PAD – 
peripheral artery disease;  PCI – percutaneous coronary intervention;  yrs – years 
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The preferred method for model development was Cox regression (77,4%). Variable selection 
methods were used in 29% (backward) and 6.5% (forward) of the studies. Other methods like choosing 
all significant variables from univariate analysis or omission of the latest weakest predictors were used 
in 12.9% and 3,2%, respectively. Discrimination was addressed in 77,4% of the developing models’ 
studies (C statistic ranged from 0.61 to 0.85). From the models published after 2008, 25.8% presented 
measures of reclassification. The presentation of the models to allow its use by others was given in 
71% of the studies. Of these, 10 studies gave a mathematical formula, and one of them did not give 
an alternative way of scoring (ex: sum points, risk chart, app). Seven of the developing model studies 
had external validation.  
2.4 Discussion 
The development and reporting of prediction models is a growing field. However, different reviews 
point out the poor quality of reporting and development issues (Table 4) (75) (76). Many studies do 
no report important information to assess its quality, reproduction or validation. In recent years, 
several publications aimed at providing tools to improve the development, validation, reporting and 
reviewing of prediction models (77). Some examples are the PROGRESS series on prognostic models 
research (78), the CHARMS checklist (38) and the TRIPOD statement (79), amongst others.  
Table 4 - Methodological issues found in cardiovascular recurrent events prediction scores development and implementation 
• Multiple scores published without practical implementation 
• Poor quality of reporting 
• Different criteria for population inclusion 
• Different types of selection of population 
• Higher proportion of men 
• Dates of enrolment 
• Population from single centre vs multicentre 
• Ethnicity and geographical origin of the population sample 
• Time of enrolment in relation to the first event 
• Time and number of assessments of the population characteristics  
• Candidate variables chosen 
• Treatment control of a variable in follow-up 
• Comorbidities, psychological and social features less studied 
• Age-bias by its prediction power 
• Difference of predictors according to age 
• Choice of outcomes 
• EPV ratio 
• Performance quality 
• External validation 
• Emphasis in global risk 
• Primary event risk factors may not work as well in the secondary setting 
• New biomarkers / proteomics 
• Genomics 
• Cost benefit analysis 
• Bias by decision-making 
• Index event bias 
• Confounders by indication 
• Presentation of score model / apps / webpage 
• Little studies from small investigators team versus joined researchers and data 
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Patients with established CV disease have nowadays an increased life expectancy, for which 
prognostic scores need to have a longer time of prediction than most models were built for. In 
secondary prediction, the time interval for risk prediction is much lower when compared to the usual 
5 to 10 years for primary event. This may lead to an underestimation of the risk in the patients with 
lower secondary risk. A lower risk at two years could become higher at 10. If the patient in question 
has a long life expectancy, a more relaxed clinical approach to this patient could lead to a disastrous 
outcome (80). In our analysis, only seven scores had prediction time of five or more years.  
2.4.1 The development of the model 
The models analysed were developed for different populations (e.g. ACS (57), atherosclerotic disease 
(15), stroke (43), PAD (58)), have different inclusion criteria, different moments of enrolment and 
assessment of features in relation to the first event, and different chosen candidate variables and 
outcomes. All these factors contribute to different models for different outcomes with different 
performances for the same populations.  
Differences in population samples are huge and this has direct influence on which patients apply the 
developed score. There are major differences between hospital admission cohorts, community 
population samples (like the Framingham cohort) or clinical trial samples. The latter has usually stricter 
inclusion criteria, less comorbidities and a better compliance (81). An example is high risk patients 
which usually are poorly represented in trials (39). Extrapolation of these scores to the real-life patient 
must be done with care. Registries with little exclusion criteria and consecutive selected patients (39), 
like the Global Registry of Acute Coronary Events (GRACE) registry (82), may unravel different 
prognosis features for which highly chosen population may not.  
Scores developed in different populations lead to different sets of selected variables. The study of 
prediction variables may vary if the developing population has previous CV event in any vascular bed 
(15)(30), or just coronary disease (55) (4) or stroke (43). Even with the same vascular bed affected as 
inclusion criteria, populations can be quite different. A score derived from the ACTION trial cohort, 
with ACS, had 56% of patients with previous MI and 5% with previous stroke (67), whereas the LIPID 
cohort, with ACS, from which long term secondary scores were also derived, had 38.4% with previous 
MI and 21.8% with previous stroke (57).  
All scores had a higher proportion of men, with over 80% in 11 of them. This raises issues when 
applying them in women (4). The recurrent event score developed from the Framingham cohort 
developed a different score for men and women (31).  
Also risk scores may behave differently in distinct populations. In healthier populations or with better 
socio-economic status, prediction scores may overestimate risk, while in sicker populations, could be 
underestimated (83). 
The dates of enrolment of population samples are also highly different (57) (68). Disease definitions, 
diagnosis and management approaches have changed in the last decades, and long periods of 
enrolment may cause big heterogeneity (84). Given the advance of medical knowledge and clinical 
practice, CV risk tended to reduce over the last decades. Thus, risk scores based in old data skew by 
overestimation of the risk (85), along with models which are outdated from contemporary clinical 
practice, which can under or overestimate the present risk (54)(86). Also, redefinition of endpoints 
over the years may affect data collection and, consequently, the results. The new emergence of 
biomarkers, genomics and proteomics may outdate some scores. 
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Scores developed using population samples from a single centre, like the SMART cohort (30), may 
differ from those which arose from a multicentre cohort (29). Also, scores developed in population 
from a specific ethnic group (54), may not apply to other ethnic groups. East Asian patients have 
similar or less rate of ischaemic events during antiplatelet therapy after PCI and a higher risk of 
bleeding when compared to Caucasian patients (87). 
One possible limitation is the inclusion of patients promptly after the occurrence of the event, since 
these patients have greater risk of recurrent events in the first weeks to months after the event (26) 
(53) (68). The timing of patient selection after the event can directly influence the final model. In 
addition, patient characteristics are usually assessed only at baseline, not considering the clinical 
management and treatment effect in the follow up, which can influence the outcome (4)(39) (88). 
In our analysis the selected variables are different between models, although coronary populations 
scores were more prevalent than atherosclerosis populations (22 versus 5). Scores from populations 
with coronary heart disease included more often age (78%), smoking disorder (63.2%), diabetes 
(57.9%), prior stroke (47.4%), gender (42.1%), renal disease (36.8%), left ventricular dysfunction 
(36.8%), prior revascularization (36.8%), hypertension (36.5%) and PAD (31.6%). Scores from 
populations with atherosclerotic disease (with proportions of coronary heart disease between 38% 
and 85%) privileged high-density-lipoprotein cholesterol (100%), smoking disorder (80%), diabetes 
(80%), renal dysfunction (80%), age (60%), gender (60%), total cholesterol (60%), systolic blood 
pressure (SBP) (60%) and triglycerides (60%). Cholesterol levels appear to have more significance for 
the stratification of events of atherosclerotic cause. Age, events in other vascular beds and organ 
damage features are more prevalent in scores for coronary patients. Other risk factors like NT-proBNP, 
which seems to have a promising role in secondary risk stratification, do not frequently appear as 
candidate variable. Some explanations may be related to cost, not being a relevant biomarker at the 
time the score was developed or laboratory availability. In our analysis, NT-proBNP was selected for 
the final score every time it was a candidate. Different choices of candidate variables will lead to 
different prediction scores, improving or worsening the final score prediction (4). 
Different comorbidities appear to have a considerable impact in secondary setting, particularly for 
longer term. This is probably related to the recovery of CV events in an older population (which gives 
comorbidity a higher weight (81)), meddling with CV therapy intolerance and dysfunction of other 
systems. Some examples are renal disease (89) (selected 75% the times it was evaluated), chronic 
obstructive pulmonary disease (COPD)(selected 75% the times) and anaemia (90)(selected 100% the 
times). These comorbidities are usually not studied as candidate variables (53), and their true value is 
yet to be validated. Patients with COPD have an increased risk of death after MI than those without 
COPD (91) (92) (93). In patients with ACS and with the same GRACE score, those with COPD have 30% 
higher risk of death than non-COPD patients (94). Introducing COPD as a predictive variable in the 
GRACE score would reclassify 33.9% from low risk to moderate risk (3% to 3%-6%) and 64.3% of the 
moderate risk were reclassified as high risk (>6%). This probably would change a different endeavour 
in the management of a considerable part of COPD and ACS patients. Anaemia has also been 
associated with a worst prognosis in CV patients (90). Some studies found the highest CV recurrent 
event rates in patients with chronic kidney disease (47) and impaired renal function at admission 
(47)(39). 
Medication use was sometimes not chosen as a candidate variable, for its leaning to confounding by 
indication (55) (15). The fact that most patients with established CV disease were already with most 
of the recommended drugs will eventually diminish its prediction power and clinical applicability (15). 
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Some studies evaluated medication as a post-hoc analysis and showed no interference with the 
estimation of prediction in the final model (55) (4).  
Other examples of variables less studied are social deprivation (72), psychological distress (49) and 
quality of life evaluation (this one addressed in a study outside this scope for a shorter period of 
prediction, still worth mentioning (95)). 
Age is one of the most powerful predictors. The increase in risk by age alone deludes into the 
suggestion that the potential benefits of therapeutic interventions are higher in the elderly than in 
younger patients. And this may lead to the decision in favour of the elderly, leaving the younger and 
the lower risk population with less stringent goals (54). Still, the costs of preventive measures to the 
young population with longer life expectancy have to be taken into account (54). Also, predictor 
variables may vary between younger and older patients. In a retrospective study (66) based on the 
SAMI cohort (53), two groups (≤ 65 years and > 65 years of age) were compared. Some factors had a 
stronger association with mortality in the younger group (renal diseases, previous MI, CABG 
treatment, hyponatraemia, anaemia and malignant neoplasm) and other in the older (significant 3-
vessel or left main coronary diseases, left atrial dilation and neurological disorders). 
The choice of the outcomes influences the model development (55). Nonfatal events are usually more 
frequent than fatal events and ACS will include angina attack and acute coronary infarction will not. 
The number of candidate variables along with the number of outcomes may be important to prevent 
overfitting. A minimum of ten events per variable has been considered the minimum for preventing 
overfitting (96) (97). In the present analysis, 7% of the models did not achieve this minimum, at the 
risk of overfitting. 
Performance measures like C statistics and net reclassification index (NRI) are important to access 
quality performance.  The C statistic is a measure of discrimination: it measures how well a model 
differentiates patients with or without the outcome. A C statistic of 0.75 means that in 75% of patients 
with and without the event, the patient with the event had a higher predicted probability than the 
patient without the event. NRI was introduced in 2008 (98) aiming to measure the improvement that 
a marker could provide to the prediction power of a model towards a given outcome. Since then, some 
published models provide NRI, showing the pool of patients that would be reclassified and therefore 
supposedly better stratified by the new model. This is a comparative measure of performance, only 
well applied when two models are compared. Given that in the secondary setting there are no 
generally accepted risk categories for long term mortality, one should note that this comparison is 
made with other published models (52). In our analysis, 82.5% of the models had measures of 
discrimination (between 0.61 and 0.94). High C-statistics, although apparently better, may conceal a 
problem of overfitting of the model, in which an optimistic performance of the model towards the 
data set from which was developed. These models perform well in that population sample but will 
perform poorly in other cohorts. Only 25.8% of the models published after 2008 presented measures 
of reclassification. The comparisons were: to the same model but restricted to demographic factors 
(72), to a model with only age and gender (65),  to a single risk factor (47), to a traditional risk factors 
model developed in the same article (74), compared to a refit Framingham model (51), compared to 
a previous developed score (56) (52). 
Accuracy (the degree to which a predicted case match an observed one) and generalizability (the 
capacity of accurate predictions in a different set of patients (54) are essential performance features. 
Validation allows to demonstrate the model accuracy in a population other than the one it was built 
for, it allows distinction between patients with and without the outcome (discrimination) and allows 
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agreement between prediction and observation of risks rates in groups with the similar risk prediction 
(99). External validation, which is to evaluate the performance of the model in a population different 
from the developing cohort is essential to the model generalisation. Most scores in our analysis lack 
internal validation and only seven had external validation (see Table 1). 
The presentation of the score to be used by other professionals is also important. Many studies do 
not present their models (55) (4) (65), while others developed apps (48), online datasheets and models 
(15) (72), as seen in  Table 1.  
2.4.2 Adaptation and validation of scores developed with different aims 
Some studies evaluated scores validated for short term prognosis but for the long-term prognosis. The 
GRACE registry gave rise to prediction scores, from in-hospital mortality (100) to mortality prediction 
at six months for patients with ACS, including STEMI (82), to several other adaptations. Several studies 
for longer term were published using the GRACE score (39) (40) or an adaptation of it (48). In the later, 
creatinine values and Killip class were substituted by history of renal dysfunction and diuretic usage, 
respectively (48), and an electronic tool providing absolute percentage risks was developed and 
externally validated.  
Several studies approached the Framingham risk score and adjusted in order to improve prediction 
and discrimination in the secondary setting: adding lifestyle changes (49) or different biomarkers 
(51)(50).  
A study evaluated scores commonly used in primary prevention (SCORE, PROCAM, FRAMINGHAM) 
concluding they had no power to predict recurrent events (46). 
Another study evaluated the prediction power of the CHA2DS2VASc score and of the Essen Stroke Risk 
Score to predict stroke, death and CV events recurrence in a first ever stroke population without atrial 
fibrillation (44). 
2.4.3 Current guidelines 
Current European Society of Cardiology guidelines consider all patients with a previous CV event to be 
at very high risk for CV mortality (17) using SCORE (19) to predict the 10 year risk of fatal CV disease 
(≥ 10%  mortality risk). American guidelines classify patients with previous events as having high risk 
(10 year risk ≥ 7.5% of coronary death or nonfatal myocardial infarction, or fatal or nonfatal stroke) 
(101), leaving the very high risk classification to patients with established CV disease and multiple 
major risk factors (especially diabetes), severe and poorly controlled risk factors (especially current 
smoking), multiple risk factors of the metabolic syndrome (especially dyslipidaemia) or progression of 
CAD (102). The SMART and the REACH cohorts risk was classified according to an adapted American 
College Cardiology/American Heart Association very high risk criteria by choosing some risk factors 
(current smokers, diabetes, dyslipidaemia, recent recurrent vascular event) (47). Other very high-risk 
factors were also selected from literature (polyvascular disease, PAD, abdominal aortic aneurysm, 
congestive heart failure and presence of atrial fibrillation, and other possible very high-risk factors 
were also considered like severe obesity, therapy resistant hypertension, hyperlipidaemia or chronic 
kidney disease). In these cohorts with patients with clinical established atherosclerotic disease, 57% 
in the SMART and 64% of the REACH cohorts were classified as very high risk (47). Events rate were 
higher in these strata (2.7 vs.2.0/100 patients-years and 5.9 vs 3.9/100 patients-years in SMART and 
REACH, respectively) but its discriminative predictive power was low (C statistic of 0.54 and 0.56 in 
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SMART and REACH).  In the former, about two thirds of the patients had an expected 10-year risk 
prediction of recurrent events <30%, and risk factors not considered in the ACC/AHA criteria like 
eGFR<45 ml/min/1.73m2, polyvascular disease or age >70 years had similar or better discriminative 
power of prediction than the ACC/AHA. Apart from the progression of coronary heart disease, the 
ACC/AHA criteria had relative low incidence rates. The criteria selected younger patients, and they 
were modifiable (quit smoking, dyslipidaemia treatment) leading to a higher range of outcomes which 
diminished its prediction power and lead to lower absolute risks (47). The authors concluded that 
current guidelines do not provide powerful tools to accurately discriminative the risk profile of 
patients with established CV disease.  
2.4.4 Other issues concerning recurrent prediction 
Traditional risk factors for primary event (smoking, cholesterol levels, hypertension or diabetes) play 
an important role. In our analysis, age, gender, diabetes and tobacco use disorder are among the most 
frequent selected variables (Table 2). Gender, total and low-density-lipoprotein cholesterol were 
selected half the times they were evaluated, hypertension a third of the times and BMI a quarter of 
times. But they may lose predictive power in the secondary prediction (4). A valid reason may be their 
better control after the first event (72). Some authors advocate that event specific lesions of CV end 
organ damage may probably improve recurrent risk score (103). These predictors may allow better 
discrimination than traditional risk factors, measuring disease burden, hemodynamic stress, 
myocardial or renal damage. Some examples are biomarkers (4) (104) like natriuretic peptides (105), 
high sensitive C-reactive protein (106), high sensitive cardiac troponin (107) or albuminuria (108) or 
the number of symptomatic  arterial beds affected (109). Other risk modifiers are usually not taken 
into account in several scores: potential prognostic variables in clinical history and examination, 
pharmacologic therapy, exercise, social deprivation, ethnicity, central obesity, several biomarkers, 
psychosocial features and family history of premature CV disease (85) (110).  
Proteomics is a major tool in the study of biomarkers. The possibility of analysing systemic proteins in 
large scale and applying these techniques to cohorts of CV risk studies followed for several years, may 
unravel new pathways of research. Ganz et al followed this approach, presenting a 4-year risk score 
for secondary event in stable coronary heart disease patients based on levels of nine proteins (51). 
The levels of 1130 proteins were measured, and, in a timeline of 4 years, 200 proteins had prognostic 
value for CV events (145 positively and 55 negatively). The final model based on nine proteins was 
compared to a refit Framingham secondary event risk model (the variables of the Framingham 
secondary event risk model readjusted to the Heart and Soul derivation cohort) (31). Proteomics 
appears to be a promising course in the prediction model investigation. A strong current limitation in 
the present time is that most of the proteins identified are not available in the traditional clinical 
setting, and cost-benefit factors need to improve. The comparison with more widely available 
biomarkers, as high sensitivity troponin or natriuretic peptide (111), has yet to be established. 
Gene investigation has associated several loci and single-nucleotide polymorphisms with 
atherosclerosis development and CAD (112) (113) . The CARDIoGRAMplusC4D Consortium identified 
15 new loci with genome-wide significance, and over 100 single-nucleotide polymorphisms (SNPs) 
with a strong association to CAD, which could explain 10.6% of CAD heredity (114). The development 
of risk scores based on the discovered SNP’s (64), with each SNP with weighted number of risk alleles, 
has been associated with recurrent events independently from risk factors. However, they were not 
associated with composite coronary death and recurrent ACS.  The authors suggest that the 
background for STEMI and NSTEMI are different: Gene risk scores are associated to atherosclerosis, 
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multivessel disease, CAD and NSTEMI, while thrombosis has an important role in MI, associated with 
smoking and probably STEMI (64).  
A cost-benefit analysis is essential when considering possible candidate variables. Balance between 
the variables required to improve secondary risk prediction and their costs must be considered. High 
costs could undermine general use, for example in primary care or developing countries. Complicated, 
long tests which need more specialised exams are also more time-consuming. 
When selecting variables, bias by decision making needs to be considered. In a study for development 
of risk prediction models for patients with coronary heart disease (55), outcomes such as CABG and 
PCI worsened the discrimination power. One explanation is the high influence of the physician decision 
for revascularization or medical treatment. In some studies, older patients with renal dysfunction are 
less often submitted to therapeutic interventions, contributing to the mortality risk increase (115). 
The therapeutic approach to older patients is more often conservative by physician choice (25) and 
lesser times based in objective criteria or validated risk scores, unlike younger patients (116). This is 
true concerning invasive procedures like CABG or PCI and target goals for hypertension or 
dyslipidaemia treatment.  
Index event bias (117) plays an important tole, yet most studies and published scores fail to address 
this matter. This may unravel several known paradoxes in the recurrent event research. Factor V 
Leiden is an undoubted risk factor for first-time deep vein thrombosis,  although in patients with 
previous event, its role has been described as apparently not important (118); smoking is an important 
risk factor for first CV event, but it seems to have a paradoxical beneficial role in patients with previous 
myocardial infarction (119); the aspirin paradox, in which patients on aspirin for primary prevention 
had lower risk for first event, but it was associated with slightly higher rates of recurrence (120); and 
the case of obesity, associated with better outcomes after the first myocardial infarction, although is 
a proven risk factor for CAD (121). In the study of the general population, the different risk factors for 
a first event are not associated with each other. Thus, to relate each risk factor with the event does 
not involve a prior biased selection of population. When we select a population based on a first event, 
the risk factors are already present in a hypothetically big part of this population, biasing the study 
towards the null (117). This bias may be different according to the intraindividual variability of the risk 
factor (122). For example, the control of a certain risk factor like blood pressure or cholesterol level 
after the event, may affect its association with recurrence. Also, unmodifiable factors will have a 
higher index event bias since they do not change and are maintained in the studied population. In 
addition, possible unknown and unmeasured risk factors, due to the selection of the population, may 
have also negative associations, affecting the accuracy of predictive models of recurrence risk (122). 
Some authors point out that markers of end-organ damage may be better predictors for recurrent 
events than clinical risk factors (4), which may be biased by the population selection. 
Confounders by indication are another known bias which may affect secondary prediction. The 
selection of patients with a specific feature which obligates certain terms (like selection of patients 
with coronary heart disease which are mostly prescribed with aspirin), may induce a misleading 
association between these later terms and some of the studied predictors which may have nothing to 
do with the terms, but with features that were inclusion criteria in the first place. So, several 
associations may not be real (86). 
Some scores were developed aiming simplicity of use (54) and practical availability in clinical practice 
(56) (68) and primary care (80). There are scores which were developed only with simple clinical 
characteristics of real life clinical practice (26) (53). Collection of data from electronic health records 
may be a faster way to analyse data, and some scores have been developed using this strategy (72). 
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This allows also to study real-life patients rather than data from selected trial cohorts. Other studies 
aimed targeting community based cohorts with few inclusion criteria aiming developing scores based 
in real life population (53). 
The use of web calculators, web datasheets or apps is a major tool for the wide diffusion of a score. 
The use of a prognostic model to stratify patients with a wide range of clinical data already available 
in real world health records without the need of extra exams is very appealing (72). The initial 
stratification could be made in a simple way, and then only a smaller part of the patients with CV 
disease would be selected for more sophisticated, time and human resources consuming and costly 
examinations. 
Finally, the abundance of prediction models is overwhelming. A systematic review of clinical prediction 
models published from 1990 to mid-2012 (123) referred 215 for patients with CAD, 78 for stroke and 
25 for sudden death. The authors noticed that they probably underestimated the total number, given 
they excluded all that did not predict a clinical outcome measure, all that were exclusive validations 
and all that did not provide enough information to calculate the individual risk probability. The number 
of prediction models made de novo is increasing over time, but the clinical application remains low. 
We are seeing a bigger effort in optimizing statistical performance than answering clinical decision 
questions (123). The pressure for publication, associated with the preference by the publishers for  
positive studies, lead to important publication bias (37). Is important to overcome publication bias 
originated by many small positive studies which mislead meta-analysis and systematic reviews with 
low grade positive associations. Different methodological procedures and statistics can affect the 
results, by enhancing, attenuating or abolishing associations (110). Also omission of some details, 
analysis and outcomes, and enhancing the importance of the findings is a major concern (110). This is 
an important issue, since it changes present knowledge and future directions of investigation.  
Whether the use of risk scores has a vital role in clinical decision-making is of utmost importance (83). 
If its use can help change how we treat patients and benefit the course of the disease is critical for its 
implementation in clinical practice. Although risk markers of deleterious outcomes are intuitively the 
focus of treatment, they are not necessarily the way to improve outcomes (124). Also, risk markers 
become more relevant when there are interventions to improve outcomes.  
Impact of research is a fundamental issue. External validations are needed. Information about the 
conditions in which the studies are made and how dependent are of those conditions is fundamental 
for the consideration of implementing the score in another setting (125).  
Some authors defend that researchers should join for critical mass; a larger amount of data would 
provide more solid prognostic research, instead of having many papers on small cohorts (110). Data 
sharing (123) and joint research may be strategic to improve the quality and validation of clinical 
prediction models, to minimize duplicate research and maximize the impact in patient outcomes. 
Nowadays, electronic databases provide a large amount of data from different populations and ethnic 
groups, which could be used by a confluence of researchers, and provide the means to develop a 
multivariate model with sound accuracy and the means to validate in other populations. This could 
lead to a single or at least few prediction models, validated in several populations, instead of 
innumerable competing models to the same problem (99). 
We should stress the need to study the impact of prognosis research. This is highly forgotten, yet a 
core area, since it could change the way we inform patients about their status and future decisions 
and clinical decision making (110).  
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2.5 Final remarks 
The major purpose of a clinical prediction model should be to aid physicians in decision making by 
estimating the probability of diagnostic or prognostic event. A model with an outstanding 
discrimination power would fail the desired clinical impact and clinical outcomes improvement if it 
does not help in clinical decision-making. 
Several issues concerning the development, the validation, the report, all the potential bias, the 
analysis cost-benefit, the implementation and the evaluation of its use are still unresolved, despite all 
the publications and investigation done. A methodologically irreprehensible study by a joint group of 
researchers worldwide could help overcoming some of the main issues pointed out and to improve 
patient stratification and consequently their treatment and quality of life. 
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3 Blood pressure and prediction of secondary 
cardiovascular events: literature review 
3.1 Introduction 
High BP is an unquestionable risk factor for CV events (17)(126)(127). Lowering high BP has a direct 
impact in diminishing first CV events (128)(129)(130).  
In the secondary prediction, high BP remains an important CV risk factor, and several published 
prediction scores for recurrent events include BP or hypertension diagnosis in their selected variables 
(31)(54)(58)(72). Still, there are a considerable number of scores in which BP variables did not achieve 
significance for prediction for recurrent events (14)(55)(60) Hypertension control with high use on 
anti-hypertensive drugs could undermine hypertension relevance in secondary prediction(14)(55)(60). 
This could explain why some recurrent event scores developed from populations with strong use of 
anti-hypertensive drugs do not have hypertension, BP or anti-hypertensive treatment in their selected 
variables in the final score (14)(55)(60). In addition, BP in patients who developed heart failure after a 
CV event could become lower thereafter, and this may affect the predictive power of BP (54)(60). 
Some authors add that traditional risk factors like hypertension may have a diminished power for 
prediction of the recurrent event than in primary prediction, and that lesions of CV end organ damage 
or biomarkers are better predictors (46) (4)(74). The population with established CV disease has high 
proportion of traditional CV risk factors, much higher than the general population. So, the first and 
the recurrent events have the same risk factors, but in the population with previous events, the high 
proportion of patients with the risk factors, undermines its predictive value (117). The prediction of 
high-risk patients for recurrent events in this population may benefit from specific markers of the true 
cause of the disease, and not indirect markers like the traditional risk factors. 
Furthermore, most studies, from trials to observational, assess the predictive power in short term. 
Although it is important to identify the patients who need intensive surveillance and care in the short-
range (14), this may lead to a devaluation of patients who seem to have a low risk in short term, but 
may have a far greater risk in the long term. The underestimation of risk in these patients may lead to 
a relaxed approach which may lead to a less fortunate outcome (80). 
To address this issue, we performed a systematic review of medical literature to investigate the long-
term predictive power of BP for recurrent CV events. 
3.2 Methods 
The development was based on the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement (131). Randomised trials, observational studies, post-hoc analysis of 
trials data and meta-analysis of patients with established CV disease (i.e. previous myocardial 
infarction, angina pectoris, unstable angina, cardiac revascularization, stroke, PAD, carotid stenosis or 
endarterectomy) were included. The articles were required to study the predictive value of BP, 
hypertension or other variables related to BP for recurrent CV event or death (i.e. all-cause mortality, 
CV mortality, myocardial infarction, angina pectoris, unstable angina, cardiac revascularization, stroke, 
PAD, carotid stenosis, endarterectomy) with a mean follow up of at least five years or more. Studies 
with reference only to statistical differences between populations, or with patients without prior CV 
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event were excluded. All types of BP measurements were admitted. Eligible articles were in English 
and concerning adults of 18 or more years. Pregnancy was an exclusion criterion. 
PICO (Population, Intervention, Comparison, Outcome) approach was used for the search strategy 
(see Table 5). The search strategy included combinations of the following keywords (MeSH (Medical 
Subject Headings) terms and truncated): myocardial infarction, myocardial ischemia, myocardial 
reperfusion, myocardial revascularization, coronary artery disease, stroke, peripheral arterial disease, 
atherosclerosis, carotid stenosis, carotid endarterectomy, cardiovascular diseases, survival analysis, 
prospective studies, prognosis, risk assessment, proportional hazard models, recurren*, secondary, 
predict*, blood pressure and hypertension. The search was limited to articles in English. 
Table 5 - PICO question of BP and prediction review 
Population Intervention Outcome 
− adults, non-pregnant 
− cardiovascular disease 
− atherosclerotic disease 
− acute coronary syndrome 
− myocardial infarction 
− CABG 
− PCI 
− STEMI 
− nonSTEMI 
− stroke 
− carotid stenosis 
− endarterectomy 
− blood pressure 
− hypertension 
− ambulatory blood pressure 
monitoring 
− prediction 
− risk factor 
− secondary cardiovascular event 
− recurrent cardiovascular event 
− death 
− mortality 
CABG – coronary artery bypass grafting; PCI – percutaneous coronary intervention; STEMI – ST elevation myocardial infarction; NSTEMI – 
non-elevation myocardial infarction 
 
During August 2018, a systematic search was performed in Ovid Medline and Cochrane databases 
from inception. Articles were selected based on titles and abstracts, according to inclusion and 
exclusion criteria. When a title or abstract raised doubts, the article was read in full. Data collected 
included: type of study, target population, dates of study, inclusion and exclusion criteria, outcomes, 
baseline characteristics of population, medication, time of retrieved information, type of statistical 
test of prediction, definition of hypertension, time of measurement of BP, description of the technique 
used, variable of prediction, adjustment and quantification. 
The risk of bias was assessed by the Quality in Prognostic Studies (QUIPS) tool (132), which was 
adapted for prognostic factor review questions and evaluated for inter-rater reliability (133). 
Analyses by type of BP variable were described. A high degree of heterogeneity between the studies 
was found: different dates leading to different variable definitions and therapy approaches, different 
type of selection and baseline characteristics of populations, distinct definitions of outcomes, BP 
variables as well as the time of measurement. These reasons lead to a preferred narrative synthesis 
of this review. 
3.3 Results 
A total of 2611 articles were screened mainly by title, selecting 243 articles which were screened by 
abstract and full text when needed (Figure 3). From these, a total of 22 articles matched the inclusion 
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criteria (see Table 6). This corresponded to 68169 patients with mean follow-up between 5 and 9.8 
years. 
Figure 3 - Search strategy for the BP and prediction review 
 
 Seven studies corresponded to post-hoc analysis of randomized clinical trials populations, 13 to 
observational studies (nine prospective and four retrospective), one cross-sectional and one meta-
analysis. Ten studies were with population with coronary ischemic disease (four with population with 
acute event and one with population submitted to PCI), nine with population with stroke (four with 
ischemic, three with stroke, one with population with haemorrhagic stroke, and one with patients 
with lacunar stroke), two with population with CV disease (stroke, coronary, peripheral) and one study 
with population submitted to carotid endarterectomy. Table 6 describes several features of different 
studies. 
Table 6 - Characteristics of the different studies concerning blood pressure and prediction review 
Study Type 
of 
study 
Population 
selected 
Follow-
up 
(years) 
Nº 
patients 
BP 
definition 
BP 
technique 
Outcome 
Bangalore 2017 
(134) Post-
hoc an 
MI 5 8658 No ✓ 
Composite (coronary death, 
nonfatal MI, resuscitated cardiac 
arrest, revascularization or 
angina) 
Schmidt 2016 
(135) 
Obs 
Ret 
Haemorrhagic 
stroke 
5 15270 No No 
Recurrent haemorrhagic stroke 
Hayden 2015 
(136) 
Obs 
Pro 
Stroke 5 177 No No 
All-cause mortality 
Kielbergerová 
2015 (137) 
Cross 
sect 
Stroke 5.4 341 No ✓ 
All-cause mortality 
Beatty 2015 (4) Obs 
Pro 
Stable CHD 6.6 912 ✓ ✓ 
Composite (time to first nonfatal 
MI, stroke or CV death) 
Lau 2014 (Neur) 
(138) 
Obs 
Pro 
Stroke 6.3 632 ✓ ✓ 
All-cause mortality, CV mortality, 
nonfatal recurrent stroke, 
nonfatal ACS 
Williams 2014 
(139) 
Obs 
Ret 
Carotid endart 5.2 79 ✓ No 
Restenosis 
Konishi 2014 
(140)  
Obs 
Ret 
PCI 9.8 4294 ✓ No 
Composite (all-cause mortality, 
ACS) 
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Study Type 
of 
study 
Population 
selected 
Follow-
up 
(years) 
Nº 
patients 
BP 
definition 
BP 
technique 
Outcome 
Park 2014 (141) Obs 
Ret 
Ischemic 
stroke 
7.6 426 ✓ ✓ 
Ischemic stroke recurrence 
Lau 2014 (AJH) 
(142) 
Obs 
Pro 
Lacunar stroke 6.5 281 ✓ ✓ 
All-cause mortality; CV mortality; 
recurrent stroke; ACS 
Cui 2009 (71) Post-
hoc an 
ACS 6 5654 No No 
CV death, MI, stroke 
Fagard 2008 
(143) 
Meta 
an 
CV disease* 6.8 302 ✓ ✓ 
All-cause mortality 
Kaplan 2006 
(144) 
Obs 
Pro 
Ischemic 
stroke 
5.4 254 ✓ No 
Recurrent stroke 
Kammersgaard 
2006 (145) 
Obs 
Pro 
Ischemic 
stroke 
5 905 ✓ No 
All-cause mortality 
Mason 2004 
(146) Post-
hoc an 
* 
CV disease** 6.5 5218 ✓ ✓ 
Composite (MI, stroke, 
revascularization, 
endarterectomy, peripheral 
artery surgery, angina pectoris, 
TIA) 
Staaf 2001 (147) Obs 
Pro 
Ischemic 
stroke 
6.5 178 ✓ No 
All-cause mortality 
Marschner 2001 
(57) 
Post-
hoc an 
ACS 6 8557 No No 
CHD death or nonfatal MI 
Herlitz 1996 
(148) 
Obs 
Pro 
MI 5 860 ✓ ✓ 
All-cause mortality 
Berger 1992 
(149) 
Obs 
Pro 
MI 5.1 363 ✓ No 
Recurrent MI 
CDPRG 1984 
(150) 
Post-
hoc an 
MI 5 2789 ✓ ✓ 
All-cause mortality 
West 2002 (151) Post-
hoc an 
ACS 6 9014 ✓ No 
Ischemic stroke 
Wilhelmsen 
2001 (152) 
Post-
hoc an 
MI 5.4 3005 No No 
Death of any cause 
CDPRG – The Coronary Drug Project Research Group; post-hoc an – post-hoc analysis of a clinical trial; Obs Pro – observational prospective; 
obs ret – observational retrospective; Meta an – meta-analysis; AJH – American Journal of Hypertension; Neur – Neurology; CHD – coronary 
heart disease; MI – myocardial infarction; ACS- acute coronary syndrome; endart – endarterectomy; PCI – percutaneous coronary 
intervention; CV- cardiovascular; TIA – transient ischemic attack;  
*- coronary heart disease; cerebrovascular disease; congestive heart failure 
** - self-reported history of myocardial infarction, angina pectoris, coronary revascularization, stroke, transient ischemic attack, carotid 
endarterectomy, peripheral artery surgery 
# - age categorized (by interval, by outcome, by both) 
 
The proportion of men ranged from 44% to 95.7%, excluding two studies that were exclusively one 
with male (150) and one with female patients (146). The prevalence of diabetes ranged from 4.4% to 
33.3% and smoking from 9% to 40%. Table 7 describes several characteristics of the population 
samples. 
Table 7 - Clinical characteristics of the different studies concerning blood pressure and prediction review 
Study Patients 
(n) 
Mean 
age 
(years) 
Men 
(%) 
Diabetes 
(%) 
Hypertension 
(%) 
Smoking 
(%) 
Time of 
assessment of 
medication 
Antihypertensive 
drugs statistics 
Statins 
(% 
defined) 
Antiplatelets 
(% defined) 
31 
Bangalore 2017 8658 # 81 11.9 32.9 20.4 Discharge ✓  ✓ 
Schmidt 2016 15270 # 52.3 4.7 ** No data Pre-event ✓ ✓  
Hayden 2015 177 76.5 46 8.6 78 40 Pre-event ✓ ✓ ✓ 
Kielbergerová 
2015 
341 69 58.9 * * 15.8 
6 months 
after event 
✓ ✓  
Beatty 2015 912 # 82.2 31.8 77.4 19.6     
Lau 2014 
(EJNeur) 
632 71 53 38 73 15 Discharge ✓   
Williams 2014 79 73 79 44 92 24     
Konishi 2014 4294 36.1 95.7 33.3 47.8 30.5 Discharge ✓ ✓ ✓ 
Park 2014 426 72 60 23 48 21 Baseline    
Lau 2014 (AJH) 281 70 52 39 74 32  ✓   
Cui 2009 5654 63 84 9.25 44.34 9.5 Pre-event  ✓ ✓ 
Fagard 2008 302 69.2 50.3 14.9 100 9.3  ✓   
Kaplan 2006 254 78.6 44 29 80 9 Baseline ✓ ✓ ✓ 
Kammersgaard 
2006 
905 73.7 51.9 21.2 34 47.1 Baseline    
Mason 2004 5218 62.1 0 16.4 64 16.8  ✓ ✓ ✓ 
Staaf 2001 178 72.5 59.55 15.2 52.2 28.1     
Marschner 
2001 
8557 62 83 9 42 10   ✓ Ɏ 
Herlitz 1996 860 # 67.62 11.36 34 34  ✓   
Berger 1992 363 67.2 64.1 17.63 48.3 35.6 baseline ✓  ✓ 
CDPRG 1984 2789 52.4 100 No data No data No data  Ɏ   
West 2002 9014 # 83.2 8.7 41.7 9.6   ✓  
Wilhelmsen 
2001 
3005 # 81.4 4.4 23.5 26.9   ✓  
CDPRG – The Coronary Drug Project Research Group; AJH – American Journal of Hypertension; EJNeur – European Journal of Neurology; 
* no data on diabetes or hypertension; 22.3% of population was treated with antidiabetics, 88.3% with anti-hypertensive drugs 
** - no data on hypertension; 37.5% of population treated with antihypertensive drugs 
Ɏ - showed multivariate analysis associated to tis medication, but not % of patients usage 
BP measurement 
Five studies used the BP measurement done at the beginning of follow-up for the analysis of prediction 
value. Two studies did not provide definition and two other did not describe the measurement 
technique. One study assumed hypertension by self-reporting of patients through questionnaire. 
Definitions, measurement techniques and outcomes are quite different (Table 8). In two studies, the 
measurement of BP did not reveal statistical power for prediction. Studies without quantification 
values were not presented (150), but the statistical analysis of elevated BP (SBP ≥ 140 or DBP ≥ 90 
mmHg) were not significant. 
 
Table 8 - Studies with blood pressure measurement 
Study 
BP / HTN 
definition 
Time meas 
Meas 
technique 
BP variable 
meas 
Notes Outcome Adjusted Stat 
Stat 
value 
95% 
CI 
p 
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Kielbergerová 
2015 
 
No data 
 
6 month after 
fisrt stroke 
 
✓ 
 
SBP ≥ 140 
and/or DBP≥90 
mmHg 
 death 
Multivar cox 
model 
HR 0.77 
0.48-
1.21 
0.255 
SBP ≥ 140 
and/or DBP≥90 
mmHg 
Including 
BNP in the 
model 
death 
Multivar cox 
model 
HR 0.86 
0.54-
1.39 
0.549 
SBP ≥ 140 
and/or DBP≥90 
mmHg 
 CV death 
Multivar cox 
model 
HR 0.83 
0.49-
1,4 
0.485 
SBP ≥ 140 
and/or DBP≥90 
mmHg 
Including 
BNP in the 
model 
CV death 
Multivar cox 
model 
HR 0.96 
0.55-
1.66 
0.875 
Kaplan 2006 
 
Prior physician 
diagnosis or 
anti-HTN 
drugs 
 
8 month after 
first stroke 
 
 
SBP ≥ 160 
 
 
Recurrent 
stroke 
Multivar 
cox model 
HR 1.86 
0.76-
4.59 
0.04 
CHD 
Multivar cox 
model 
HR 1.22 
0.58-
2.57 
0.44 
Combined 
vascular events 
Multivar cox 
model 
HR 1.27 
0.67-
2.42 
0.12 
All-cause 
mortality 
Multivar cox 
model 
HR 0.74 
0.45-
1.21 
0.91 
Mason 2004 
 
Self reported 
meas in 
questinnaire 
 
baseline 
 
 
SBP (per  10 
mmHg) 
Only age 
adjust 
CV events* 
Multivar cox 
model 
RR 1.09 
1.09-
1.15 
 
DBP (per  10 
mmHg) 
 CV events* 
Multivar cox 
model 
RR 1.06 
0.97-
1.16 
 
MAP (per  10 
mmHg) 
Only age 
adjust 
CV events* 
Multivar 
cox model 
RR 1.22 
1.14-
1.29 
 
MAP (per  10 
mmHg) 
 CV events* 
Multivar 
cox model 
RR 1.10 
1.02-
1.18 
 
PP (per  10 
mmHg) 
Only age 
adjust 
CV events* 
Multivar 
cox model 
RR 1.18 
1.12-
1.23 
 
PP (per  10 
mmHg) 
 CV events* 
Multivar 
cox model 
RR 1.10 
1.03-
1.15 
 
West 2002 
 
Anti-HTN 
drugs or > 
160-95 mmHg 
 
baseline 
 
 
 
SBP 126-140 
mHg 
 
Non-
hemorrhagic 
stroke 
Multivar 
cox model 
RR 1.48 
1.11-
1.97 
0.004 
SBP > 140 
mmHg 
 
Non-
hemorrhagic 
stroke 
Multivar 
cox model 
RR 1.63 
1.21-
2.18 
0.004 
Wilhelmsen 
2001 
 
No data 
 
baseline 
 
 
SBP ≥ 146 
mmHg  
Placebo 
group 
Coronary 
events 
Logistic 
regression 
RR 0.99 
0.8-
1.21 
0.21 
DBP 
Placebo 
group 
Coronary 
events 
Logistic 
regression 
RR 1.14 
0.91-
1.43 
0.18 
BNP – brain natriuretic peptide; BP – blood pressure; CI – confidence interval; CV – cardiovascular; DBP – diastolic blood pressure; HR – 
hazard ratio; HTN - hypertension MAP – median arterial pressure; Meas – measurement; multivar – multivariate; PP – pulse pressure; RR – 
relative risk; stat – statistic; SBP – systolic blood pressure 
 
Hypertension 
Previous diagnosis of hypertension was evaluated in several articles (Table 9). Definition of 
hypertension is not homogeneous between studies, and six studies did not provide definition. Six 
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studies fail to show that hypertension has predictive power for the recurrent event. Studies without 
quantification values were not presented (4), but the statistical analysis of hypertension was not 
significant. On study addressed the outcome survival instead of death, but it was considered (139). 
Table 9 - Studies that assessed previous diagnosis of hypertension 
Study 
BP / HTN 
definition 
Time 
meas 
Meas 
technique 
BP 
variable 
meas 
Notes Outcome Adjusted Stat 
Stat 
value 
95% CI p 
Hayden 2015 No data baseline No data HTN  death univar HR 1.68  0.06 
Williams 2014 
HTN: BP≥ 
140/90 or 
anti-HTN 
drugs 
baseline No data HTN  survival multivar HR 0.78 
0.24-
3.51 
0.72 
Konishi 2014 
HTN: BP≥ 
140/90 or 
anti-HTN 
drugs 
baseline No data HTN  
Composite 
(all-cause 
death, ACS) 
univar HR 1.87 
0.59-
6.37 
0.28 
Park 2014 No data 
2 weeks 
after first  
stroke 
No data HTN  
All-cause 
death 
 
univar 
HR 0.862 
0.619-
1.202 
0.381 
Lau 2014 
(EJNeur) 
 
HTN: BP≥ 
140/90 or 
anti-HTN 
drugs 
baseline 
 
✓ 
 
HTN 
 
 
All-cause 
mortality 
Cox multiv 
analysis 
HR 0.71 
0.41-
1.24 
 
CV mortality 
Cox multiv 
analysis 
HR 0.59 
0.20-
1.70 
 
Recurrent 
stroke 
Cox multiv 
analysis 
HR 0.91 
0.42-
1.95 
 
ACS 
Cox multiv 
analysis 
HR 1.08 
0.31-
3.72 
 
Cui 2009 
 
No data 
 
baseline 
 
No data 
 
HTN 
 
Cox with 
polynomial 
CV death, MI, 
ischemic or 
haemorrhagic 
stroke 
Cox multiv 
analysis 
HR 1.18 
1.04-
1.35 
 
Cox model 
with no lab 
data 
CV death, MI, 
ischemic or 
haemorrhagic 
stroke 
Cox multiv 
analysis 
HR 1.21 
1.06-
1.38 
 
Kammersgaard 
2006 
HTN: BP≥ 
160/95 or 
anti-
hypertensive 
drugs 
baseline No data HTN  
All-cause 
death 
Multiv HR NS NS 0.54 
Staaf 2001 
 
No data 
 
baseline 
 
No data 
 
HTN  
Recurrent 
stroke 
univariate 
No 
data 
No 
data 
No 
data 
< 0.05 
Recurrent 
stroke 
Cox multiv 
analysis 
No 
data 
No 
data 
No 
data 
0.025 
Marschner 
2001 
No data baseline No data HTN  
Coronary 
death or 
nonfatal MI 
Cox multiv 
analysis 
HR 1.14 
1.01-
1.28 
0.035 
Herlitz 1996 
 
Self-reported 
 
baseline 
 
Self-
reported 
HTN 
 
Adjusted for 
age, sex, 
previous MI, 
angina, DM, 
All-cause 
death 
Multivar 
logistic 
regression 
No 
data 
No 
data 
No data NS 
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BP / HTN 
definition 
Time 
meas 
Meas 
technique 
BP 
variable 
meas 
Notes Outcome Adjusted Stat 
Stat 
value 
95% CI p 
 HTN, CHF, 
smoking 
Adjusted for 
age, sex, 
previous MI, 
angina, DM, 
HTN, CHF, 
smoking, 
coronary unit 
admission  
All-cause 
death 
Multivar 
logistic 
regression 
No 
data 
No 
data 
No 
data 
0.048 
Adjusted for 
age, sex, HTN 
Recurrent MI 
Multivar 
logistic 
regression 
No 
data 
No 
data 
No 
data 
< 0.05 
Berger 1992 
HTN: BP > 
160/95 or 
anti-HTN 
drugs 
baseline No data HTN  
Recurrent MI 
(men) 
Logistic 
regression 
adjusted to 
sex 
OD 2.3 1.1-4.8  
West 2002 
HTN: BP > 
160/95 or 
anti-HTN 
drugs 
baseline No data HTN  
Non-
haemorrhagic 
stroke 
Cox multiv 
analysis 
RR 1.35 
1.08-
1.69 
< 0.008 
Wilhelmsen 
2001 
 
No data 
 
baseline 
 
No data 
 
HTN 
 
Placebo 
group* 
Coronary 
events 
Multivar 
logistic 
regression 
RR 1.23 
1.03-
1.46 
0.024 
Simvastatin 
group* 
Coronary 
events 
Multivar 
logistic 
regression 
RR 1.35 
1.07-
1.71 
0.013 
ACS – acute coronary syndrome; BP – blood pressure; CHF – congestive heart failure; CI – confidence interval; CV – cardiovascular; DM – 
diabetes mellitus; HTN – hypertension; meas – measurement; MI – myocardial infarction; multivar – multivariate; NS – nonsignificant; RR – 
relative risk; Stat – statistic; Univar – univariate;  
*4S trial (Scandinavian Simvastatin Survival Study (152), double blind randomized placebo controlled trial for long-term simvastatin or 
placebo in coronary heart disease patients 
 
Anti-hypertensive treatment 
Anti-hypertensive treatment was used as a synonym of diagnosis of hypertension in several studies 
(138)(145)(151). In our sample, only one study evaluated its long-term predictive power (Table 10). 
Table 10 - Studies that assessed previous anti-hypertensive treatment 
Study 
BP / HTN 
definition 
Time 
meas 
Meas 
technique 
BP 
variable 
meas 
Notes Outcome Adjusted Stat 
Stat 
value 
95% 
IC 
p 
Schmidt 
2016 
No data Baseline No data   
Intracerebral 
haemorrhage 
Multivar 
Poisson 
regression 
Rate 
ratio 
0.78 
0.66-
0.91 
 
BP – blood pressure; CI – confidence interval; HTN – hypertension; meas – measurement; multivar – multivariate; Stat – statistic 
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Ambulatory blood pressure monitoring 
ABPM 24 hours was evaluated in two studies, an observational retrospective study (141) and a 
metanalysis (143), and several variables measured  by the ABPM were evaluated (Table 11). 
Table 11 - Studies that assessed ambulatory blood pressure monitoring 24 hours 
Study 
BP / HTN 
definition 
Time meas 
Meas 
technique 
BP variable 
meas 
Notes Outcome Adjusted Stat 
Stat 
value 
95% CI p 
Park 
2014 
 
Nocturnal 
systolic fall, 
dipper, non-
dipper, 
extreme 
dipper, 
reverse 
dipper 
 
2 weeks 
after 
ischemic 
first stroke 
 
✓ 
 
Daytime 
mean SBP 
Adjusted for 
extreme 
dipper 
Recurrent 
ischemic 
stroke 
Cox multiv 
analysis 
HR 1.014 
1.002-
1.026 
0.017 
Extreme 
dipper 
Adjusted for 
daytime 
mean SBP 
Recurrent 
ischemic 
stroke 
Cox multiv 
analysis 
HR 1.833 
0.655-
5.124 
0.248 
Daytime 
mean SBP 
 
All-cause 
death 
univar HR 1.001 
0.992-
1.1010 
0.776 
Nighttime 
SBP 
Adjusted for 
reverse 
dipper 
All-cause 
death 
Cox multiv 
analysis 
HR 1.001 
0.990-
1.011 
0.878 
Reverse 
dipper 
Adjusted for 
night-time 
SBP 
All-cause 
death 
Cox multiv 
analysis 
HR 1.676 
1.155-
2.433 
0.007 
Daytime 
mean DBP 
 
All-cause 
death 
univar HR 0.980 
0.966-
0.994 
0.05 
Fagard 
2008 
✓ ✓ ✓ 
24 h SBP 
Adjusted for 
office BP 
All-cause 
death 
Cox multiv 
analysis 
HR 1.09 
0.84-
1.43 
 
Nighttime 
SBP 
Adjusted for 
office BP 
All-cause 
death 
Cox multiv 
analysis 
HR 1.24 
0.99-
1.56 
 
Daytime SBP 
Adjusted for 
office BP 
All-cause 
death 
Cox multiv 
analysis 
HR 0.97 
0.74-
1.28 
 
24 h SBP 
Unadjusted 
for office BP 
All-cause 
death 
Cox multiv 
analysis 
HR 1.12 
0.88-
1.44 
 
Nighttime 
SBP 
Unadjusted 
for office BP 
All-cause 
death 
Cox multiv 
analysis 
HR 1.26 
1.02-
1.56 
≤ 0.05 
Daytime SBP 
Unadjusted 
for office BP 
All-cause 
death 
Cox multiv 
analysis 
HR 1.01 
0.87-
1.39 
 
24 h SBP 
Adjusted for 
office BP 
CV death 
Cox multiv 
analysis 
HR 1.23 
0.88-
1.71 
 
Nighttime 
SBP 
Adjusted for 
office BP 
CV death 
Cox multiv 
analysis 
HR 1.41 
1.06-
1.87 
≤ 0.05 
Daytime SBP 
Adjusted for 
office BP 
CV death 
Cox multiv 
analysis 
HR 1.06 
0.75-
1.49 
 
24 h SBP 
Unadjusted 
for office BP 
CV death 
Cox multiv 
analysis 
HR 1.23 
0.91-
1.66 
 
Nighttime 
SBP 
Unadjusted 
for office BP 
CV death 
Cox multiv 
analysis 
HR 1.40 
1.08-
1.81 
≤ 0.01 
Daytime SBP 
Unadjusted 
for office BP 
CV death 
Cox multiv 
analysis 
HR 1.09 
0.79-
1.50 
 
24 h SBP 
Adjusted for 
office BP 
CV events 
Cox multiv 
analysis 
HR 1.20 
0.91-
1.58 
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BP / HTN 
definition 
Time meas 
Meas 
technique 
BP variable 
meas 
Notes Outcome Adjusted Stat 
Stat 
value 
95% CI p 
Nighttime 
SBP 
Adjusted for 
office BP 
CV events 
Cox multiv 
analysis 
HR 1.34 
1.06-
1.69 
≤ 0.01 
Daytime SBP 
Adjusted for 
office BP 
CV events 
Cox multiv 
analysis 
HR 1.03 
0.77-
1.36 
 
24 h SBP 
Unadjusted 
for office BP 
CV events 
Cox multiv 
analysis 
HR 1.19 
0.92-
1.53 
 
Nighttime 
SBP 
Unadjusted 
for office BP 
CV events 
Cox multiv 
analysis 
HR 1.32 
1.06-
1.65 
≤ 0.01 
Daytime SBP 
Unadjusted 
for office BP 
CV events 
Cox multiv 
analysis 
HR 1.04 
0.80-
1.36 
 
Nighttime 
SBP 
Adjusted for 
daytime SBP 
All-cause 
death 
Cox multiv 
analysis 
HR 1.41 
1.07-
1.85 
≤ 0.01 
Nighttime 
SBP 
Adjusted for 
daytime SBP 
CV death 
Cox multiv 
analysis 
HR 1.57 
1.12-
2.19 
≤ 0.01 
Nighttime 
SBP 
Adjusted for 
daytime SBP 
CV events 
Cox multiv 
analysis 
HR 1.49 
1.13-
1.98 
 
Nighttime 
DBP 
Adjusted for 
daytime DBP 
All-cause 
death 
Cox multiv 
analysis 
HR 1.32 
1.00-
1.74 
≤ 0.05 
Nighttime 
DBP 
Adjusted for 
daytime DBP 
CV death 
Cox multiv 
analysis 
HR 1.43 
1.03-
2.00 
≤ 0.05 
Nighttime 
DBP 
Adjusted for 
daytime DBP 
CV events 
Cox multiv 
analysis 
HR 1.38 
1.04-
1.83 
≤ 0.05 
BP – blood pressure; CI – confidence interval; CV- cardiovascular; DBP – diastolic blood pressure; HTN – hypertension; HR – hazard ratio; 
meas- measurement; multivar – multivariate; SBP – systolic blood pressure; stat- statistic 
BP variability 
BP variability was addressed in several studies (Table 12). Definitions and calculations are different, 
according to literature.  
Table 12 - Studies that assessed blood pressure variability 
Study 
BP / HTN 
definition 
Time meas 
Meas 
technique 
BP 
variable 
meas 
Notes Outcome Adjusted Stat 
Stat 
value 
95% IC p 
Bangalore 
2017 
 
SBPV – 
average of 
absolute 
difference 
between 
successive 
values 
 
Month 3 
and 6 
after first 
, and 6/6 
months 
thereafter 
(5 years) 
 
 
SBPV 
by 
average 
Adjustment: 
trial 
treatment, 
LDL 
variability, 
baseline 
charact 
Composite 
coronary 
death, 
nonfatal 
MI, 
resuscitate 
cardiac 
arrest, 
revascular, 
angina 
Cox 
multiv 
analysis 
HR 1.07 
1.04-
1.11 
0.0001 
SBPV 
by 
average 
Adjustment: 
trial 
treatment, 
LDL 
variability, 
baseline 
charact 
Any CV 
event 
Cox 
multiv 
analysis 
HR 1.08 
1.05-
1.11 
0.0001 
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BP / HTN 
definition 
Time meas 
Meas 
technique 
BP 
variable 
meas 
Notes Outcome Adjusted Stat 
Stat 
value 
95% IC p 
SBPV 
by 
average 
Adjustment: 
trial 
treatment, 
LDL 
variability, 
baseline 
charact 
Death 
Cox 
multiv 
analysis 
HR 1.2 
1.14-
1.25 
0.0001 
SBPV 
by 
average 
Adjustment: 
trial 
treatment, 
LDL 
variability, 
baseline 
charact 
Fatal and 
non fatal 
stroke 
Cox 
multiv 
analysis 
HR 1.33 
1.2-
1.47 
0.0001 
DBPV 
by 
average 
Adjustment: 
trial 
treatment, 
LDL 
variability, 
baseline 
charact 
Composite 
CHD 
death, 
nonfatal 
MI, 
resuscitate 
cardiac 
arrest, 
revascular, 
angina 
Cox 
multiv 
analysis 
HR 1.11 
1.06-
1.16 
0.0001 
DBPV 
by 
average 
Adjustment: 
trial 
treatment, 
LDL 
variability, 
baseline 
charact 
death 
Cox 
multiv 
analysis 
HR 1.29 
1.20-
1.39 
0.0001 
Lau 2014 
(AJH) 
 
 
HTN ≥ 
140/90 
mmHg or 
anti-
hypertensive 
drugs; BPV 
by the coefV 
Follow up 
visits 3-
4/3-4 
months 
 
✓ 
coefV 
SBPV 
(last 
quartil) 
 CV death 
Bivariate 
(mean 
BP) 
HR 2.77 
1.23-
6.23 
 
coefV 
SBPV 
(3rd 
quartil) 
 CV death 
Bivariate 
(mean 
BP) 
HR 1.70 
0.72-
4.06 
 
coefV 
SBPV 
(last 
quarti) 
 CV death 
Cox 
multiv 
analysis 
HR 2.36 
1.02-
5.49 
 
coefV 
SBPV 
(3rd 
quartil) 
 CV death 
Cox 
multiv 
analysis 
HR 1.64 
0.68-
3.98 
 
coefV 
DBPV 
(last 
quartil) 
 CV death 
Bivariate 
(mean 
BP) 
HR 1.25 
0.57-
2.75 
 
coefV 
DBPV 
(3rd 
quartil) 
 CV death 
Bivariate 
(mean 
BP) 
HR 1.69 
0.80-
3.59 
 
coefV 
DBPV 
 CV death 
Cox 
multiv 
analysis 
HR 1.49 
0.69-
3.20 
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BP / HTN 
definition 
Time meas 
Meas 
technique 
BP 
variable 
meas 
Notes Outcome Adjusted Stat 
Stat 
value 
95% IC p 
(last 
quartil) 
coefV 
DBPV 
(3rd 
quartil) 
 CV death 
Cox 
multiv 
analysis 
HR 1.20 
0.54-
2.67 
 
coefV 
SBPV 
(last 
quartil) 
 
All-cause 
death 
Bivariate 
(mean 
BP) 
HR 1.79 
1.16-
2.75 
 
coefV 
SBPV 
(3rd 
quartil) 
 
All-cause 
death 
Bivariate 
(mean 
BP) 
HR 1.23 
0.77-
1.95 
 
coefV 
SBPV 
(last 
quartil) 
 
All-cause 
death 
Cox 
multiv 
analysis 
HR 1.46 
0.88-
2.43 
 
coefV 
SBPV 
(3rd 
quartil) 
 
All-cause 
death 
Cox 
multiv 
analysis 
HR 1.18 
0.77-
1.80 
 
coefV 
DBPV 
(last 
quartil) 
 
All-cause 
death 
Bivariate 
(mean 
BP) 
HR 1.18 
0.77-
1.95 
 
coefV 
DBPV 
(3rd 
quartil) 
 
All-cause 
death 
Bivariate 
(mean 
BP) 
HR 0.89 
0.57-
1.39 
 
coefV 
DBPV 
(last 
quartil) 
 
All-cause 
death 
Cox 
multiv 
analysis 
HR 1.03 
0.62-
1.69 
 
coefV 
DBPV 
(3rd 
quart) 
 
All-cause 
death 
Cox 
multiv 
analysis 
HR 0.88 
0.52-
1.48 
 
Lau 2014 
(EJNeur) 
HTN ≥ 
140/90 
mmHg or 
anti-
hypertensive 
drugs; BPV 
by the coefV 
drugs; BPV 
by the coefV 
Follow up 
visits 3-
4/3-4 
months 
✓ 
SBP SD 
(3rd tert 
>17.5 
mmHg) 
 
All-cause 
death 
Cox 
multiv* 
analysis 
HR 1.97 
1.02-
3.80 
< 0.05 
SBP SD 
(2nd tert 
13-17.5 
mmHg) 
 
All-cause 
death 
Cox 
multiv* 
analysis 
HR 1.47 
0.74-
2.90 
 
SBP SD 
(3rd tert 
>17.5 
mmHg) 
 CV death 
Cox 
multiv* 
analysis 
HR 7.64 
1.65-
35.41 
< 0.01 
SBP SD 
(2nd tert 
13-17.5 
mmHg) 
 CV death 
Cox 
multiv* 
analysis 
HR 2.00 
0.36-
11.21 
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BP / HTN 
definition 
Time meas 
Meas 
technique 
BP 
variable 
meas 
Notes Outcome Adjusted Stat 
Stat 
value 
95% IC p 
SBP SD 
(3rd tert 
>17.5 
mmHg) 
 
Recurrent 
stroke 
Cox 
multiv* 
analysis 
HR 1.14 
0.51-
2.56 
 
SBP SD 
(2nd tert 
13-17.5 
mmHg) 
 
Recurrent 
stroke 
Cox 
multiv* 
analysis 
HR 0.95 
0.41- 
2.19 
 
SBP SD 
(3rd tert 
>17.5 
mmHg) 
 ACS 
Cox 
multiv* 
analysis 
HR 2.13 
0.62-
7.35 
 
SBP SD 
(2nd tert 
13-17.5 
mmHg) 
 ACS 
Cox 
multiv* 
analysis 
HR 0.95 
0.41-
2.19 
 
ACS – acute coronary syndrome; AJH – American Journal of Hypertension; BPV – blood pressure variability; CI – confidence interval; charact 
– characteristics; DBPV – diastolic blood pressure variability; coefV – coefficient of variation; EJNeur – European Journal of Neurology; HR – 
hazard ratio; stat- statistic; LDL – low-density-lipoprotein cholesterol; multiv – multivariate; ; SBPV – systolic blood pressure variability; SD – 
standard deviation; tert – tertile 
* with mean SBP and mean DBP 
3.4 Discussion 
There is consistent evidence that BP values are a main risk factor for primary (126)(127) and secondary 
CV events (153)(154)(155) and treatment of hypertension for prevention of secondary outcomes is 
mandatory. But whether hypertension or BP values have a place in secondary predicting scores is less 
clear.  
Our selection has a wide range of differences: in basic populations (nine with coronary heart disease, 
nine with stroke, two with established CV disease, one after carotid endarterectomy and one after 
PCI). A considerable part (31.8%) did not give BP variable definition, and more than half (54.0%) did 
not describe the technique, raising limitations to accurately compare studies. Some of the older 
studies used hypertension criteria of 160/90 mmHg, which changes the stratification of the population 
and its correlation with events. The lack of complete information concerning the measurement 
methodology of BP in research papers is a bias for the accurate comparison of results (156). 
Characteristics heterogeneity such as age, sex, comorbidities and medication highly influence the 
statistical significance of the studied variables. Medication was not quantitively addressed in 45.5% 
(11/22) for anti-hypertensive treatment, 54.5% (12/22) for statins and 63.6% (14/22) for the use of 
anti-platelets agents. Lack of information of control of BP values throughout follow-up is a major issue. 
No study addressed this matter, and this could help to understand differences between the value of 
predictive power concerning BP. In addition, the studies were developed in a wide time range, during 
which medical knowledge, behaviours and therapeutic strategies changed, which also influences the 
role of predictive values. 
In our analysis, several studies have not found an established predictive value for history of 
hypertension or BP levels. Eight studies (36.4%) did not find any predictive power for the variables of 
BP studied  (4)(135)(136)(137)(139)(140)(145)(152). Others had significant results found for specific 
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outcomes, like SBP≥ 160 mmHg for stroke (but not for coronary events, all CV events or all-cause 
mortality) (144) or for variability visit-to-visit, but not for the diagnosis of hypertension (142).  
In some scores, the use of hypertension as a predictive variable did not affect the model performance 
(54) or had no predictive power(139)(140) in survival analysis. This does not change the fact it remains 
an undoubted risk factor which must be controlled in secondary prevention. 
The use of BP values, although an established strategy in many primary prediction scores (19)(20), is 
not as well supported in the secondary practice (137)(144)(152). To use the BP measured in one 
unique medical appointment, for example at baseline, which happens in several studies, as a predictor 
for recurrent events not be the best option. The use of measured BP values from hypertensive treated 
patients may underestimate the true value of associated risk (54)(157). Also, in our analysis, the use 
of hypertension as a variable reached statistical significance for risk of recurrence in several 
articles(57) (71)(147) (148)(149)(151)(152), but not for six others (136) (138)(139)(140)(141)(145).The  
first set mostly included older studies and all except one were based on ischemic heart disease 
patients. The second set globally comprised more recent studies and all but one were based on stroke 
or carotid disease populations. This may point that hypertension and BP have an important role in 
some specific CV events, but less strong in others.  
The concept that statistical performance may be worked to improve statistical significance is also 
relevant. The work by Herlitz et all (148) shows that hypertension is not predictive in a specific 
multivariate model, by adding whether or not admission in intensive care unit changed the significance 
of the predictive value of hypertension. Sometimes the focus is mainly in highlighting the statistical 
performance of the models (123), but this undermines the ability to truly find the best predictive 
variables for recurrent events. 
Using ABPM 24 hours allows to evaluate BP along the 24 hours, including the nocturn pattern. In our 
sample, two studies qualified for long term prediction. One, based on stroke patients,  found 
significance in the daytime mean SBP, daytime mean DBP and the reverse dipper pattern (141), in 
univariate and multivariate analysis (adjustments seen in Table 11). A meta-analysis of 3 studies with 
patients with CV disease (coronary, cerebrovascular, peripheral) found a consistent significance in 
nocturnal SBP for all-cause mortality, CV death and CV events (143). In this way, to measure BP in 
office for stratifying patients will fall short, and to evaluate the night pattern may be a more accurate 
tool. 
Variability of BP is being studied as a main CV risk for several years (126). In our analysis three studies 
based on two populations, one with previous myocardial infarction (134) and one with previous stroke 
(138)(142) associated variability of visit-to-visit SBP to secondary outcomes. Evaluations by average of 
absolute difference between successive values, coefficient of variation and standard-deviation (SD) 
were used, to predict all-cause mortality and CV death. Coefficient of variation and SD only showed 
significance in their higher values (last quartile and tercile)(138) (142).  
The concept of index event bias competing risks may also have a stronger role in secondary setting, 
since several risk factors conglomerate highly in patients with established CV disease (117). Instead of 
traditional risk factors maintaining the gold standard in secondary prediction, as in the primary setting, 
some authors defend that specific disease organ lesions and targeted biomarkers may be of higher 
importance in secondary prediction (158)(56)(104). 
Limitations for this study are the criteria for inclusion of articles only written in English may have 
discarded some papers, but the long-follow-up is somehow difficult to attend and may have attenuate 
this limitation. Also, the inclusion in the search strategy of at least one of “survival analysis, 
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prospective studies, prognosis, risk assessment, proportional hazard models” may have excluded 
articles which were not classified with none of these. The highly different methods, definitions, 
populations, items measured, and outcomes limits the true comparison between studies. 
3.5 Final Remarks 
The literature reports a wide variety on results concerning the predictive power of BP, hypertension 
or associated variables, with respect to recurrent CV events prediction at long term. Although BP is a 
strong undisputed CV risk factor, which is mandatory to be controlled, its place in prediction models 
for recurrent events may need further evaluation. BP may remain important for prediction in specific 
target lesion populations, but it may weaken the predictive power in others. The use of prior diagnosis 
of hypertension or the BP measurement of one single visit may not be the best way to use the 
information given by BP in secondary prediction. Other methods like ABPM or variability should be 
considered. Further investigation of BP contribution to recurrent events prediction can benefit from 
aggregating information from several existing trials, as well from the prospectively study of 
information given by traditional risk factors, including BP, along with new specific end organ lesion or 
biomarkers. 
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4 Role of ABPM in prediction of cardiovascular events: 
literature review 
Arterial hypertension is one of the major risk factors for CV disease (159)(160)(161). It is largely 
associated with stroke (162) and coronary heart disease (163). CV disease is a global wide public health 
problem, and in Portugal is the first cause of death (164). In 2015, in Portugal the death rates for stroke 
and ischaemic heart disease were, respectively, 58.4 and 51.5 deaths per 100,000 people (164). 
The association between hypertension and CV disease has mostly been investigated using office BP. 
The reduction of BP has been associated with a decrease in CV events (165)(166). 
There are some known issues in relation to office BP being ABPM the most accurate way of evaluating 
BP, concerning technical issues, white-coat effect and variability (167) (168)(169). Several authors 
alert to the importance of the errors in BP determination in routine clinical office, and advocate out-
of-office BP measurement, particularly ABPM, as the preferred method to evaluate and approach BP 
(156)(170). 
ABPM is a recognized method for the diagnosis of hypertension, to assess the efficacy of treatment 
and the long term control of BP values (171). It has other advantages over office BP: it provides greater 
information considering the 24 hour pattern on systolic and diastolic blood pressure, heart rate and 
measures of variability in the patient usual daily environment and permits the recognition of masked 
and white-coat hypertension (168).  
It is nowadays well known the better performance of ABPM concerning prediction of hypertension 
mediated organ damage (172) and CV events (173)(174)(175). Recent guidelines and position papers 
stated the superiority of ABPM over office BP measurement in the prediction of CV morbidity and 
mortality (126)(176) (177). Several articles addressed the higher predictive value of ABPM for death 
or CV events in several populations: general patients in primary care (174) and population based 
studies (178)(173)(179), hypertensive patients (7)(180)(181)(175), treated hypertensive patients 
(182), elderly patients (183)(184), resistant hypertension (185)(186), patients with isolated SBP (187), 
untreated patients (188), diabetics (189) and patients on haemodialysis (190). 
In primary prediction, the ABPM variables and patterns most associated with worst outcomes have 
been identified. 
Night-time BP appears to be a better predictor of outcomes than daytime (7)(191)(192). The dipping 
pattern and the night-time/daytime BP ratio are significant and independent predictors of CV events 
(8)(193), stroke (180), and coronary events (180). Non-dipping (8)(176), reverse dipping (194) and 
extreme dipping (195) have been associated to a higher risk for CV events than dipping. Extreme 
dipping has been associated also to silent cerebral lesions (184). 
Increase in SBP (24 hours, daytime and night-time) has been associated in several studies with 
increased stroke, CV mortality, total mortality and cardiac events (196)(197). Other ABPM variables 
have significant predictive value for CV outcomes: increased BP night-time variability  (198)(199), 
increased systolic and diastolic 24-hour variability (200), increased pulse pressure (196)(201) and 
increased morning surge (202)(203)(204), but their significance for clinical practice has not well 
defined in recent guidelines (126).  
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In patients with established CV disease, studies addressing the predictive value of ABPM to CV events 
are scarce. Some address to the relevance of night-time (143), the dipping pattern (141), and the 
variability (205), but results are not conclusive. 
A study evaluating high-risk patients and comparing differences between office BP and ABPM 
variables showed a high prevalence of non-dipping pattern in high-risk patients when comparing with 
lower risk patients (206). 
Fagard et al performed a meta-analysis of 302 patients with established CV disease (143). There was 
an association between night-time BP and death and recurrent CV events, and the night-day BP ratio 
and the dipping pattern were associated with CV outcomes (143). 
In patients with stroke, high 24-hour SBP has been associated as an independent predictor for CV 
events (6)(207). Non-dipping pattern was associated with higher risk for stroke, in a observational 
study comparing stroke survivors with controls (208). In patients with lacunar stroke, high risk of brain 
microbleeds was associated to 24-hour, day and night SBP and DBP (209). In another study in patients 
with lacunar ischemic lesions, high 24 hour SBP and 24 hour DBP, night-time BP and a lower nocturnal 
BP dip were related with silent ischemic cerebral lesions and stroke (210). Also SBP and dipping 
patterns have been associated with cognitive impairment and dementia in patients with previous 
stroke (207)(211).  
Night-time SBP has been related with CV event in a cohort of high-risk patients, but only nearly 30% 
of them had previous CV event (212) 
In some studies, ABPM variability in stroke patients did not show association with recurrent stroke 
(205) or CV events (213). A study comparing diabetic and non-diabetic stroke survivors, found 
association of BP variability for CV outcomes in non-diabetic stroke patients, but not in the diabetic 
(214). Another study related several measures of ABPM variability (coefficient of variation, standard-
deviation, average real variability) with small vessel disease progression (215).  
Mean 24 hour DBP and mean 24 hours heart rate has been associated with CV events in a study with 
acute myocardial infarction patients (216). ABPM was performed 3 weeks after the first acute event 
and variables associated with risk at 1 year were introduced in a score to identify high-risk populations 
(216).  
 
ABPM is associated with CV events, and there is association between several variables and outcomes 
in primary prediction. In secondary prediction, the studies are few and inconclusive, although some 
studies indicate a clear association between ABPM variables and CV outcome. More studies are 
needed in order to evaluate if ABPM could be a reliable predictor for high risk patients that already 
had a CV event.
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5 Methods 
Between 1991 and 2007, a cohort of 1200 patients without established CV disease and previously 
referred for ABPM was followed for CV events. The description of the methods and results of this 
study was previously published (7). In brief, 1200 hypertensive patients referred to ABPM were 
followed for 8.2 ± 3.1 years, with 152 CV events being reported. These patients were subsequently 
reviewed. Those who repeated 24 hour-ABPM after the event and fulfil the remaining inclusion criteria 
were selected. 
To these selected patients were added all patients with prior CV event and referred to ABPM at Centro 
Hospitalar do Baixo Vouga between 1996 and 2017.   
The inclusion criteria comprised: 
• aged 18 years and older; 
• confirmed CV event (myocardial infarction, unstable angina with hospital admission, 
myocardial revascularization, stroke, endarterectomy or bypass surgery for PAD, carotid 
endarterectomy); 
• referred to ABPM at any point after the event; 
• possibility of obtaining updated and accurate clinical information by August 2018, including 
death cause if applicable; the allowed sources of information were: normal scheduled clinical 
appointment, by the individual physician of each patient and clinical records; 
• ABPM valid information of 85% or more. 
Exclusion criteria were:  
• pregnancy; 
• patients who could not be further evaluated in follow-up examination.  
The ABPM records between 2013 and 2014 were lost due to a failure in the hospital information 
system and these two years could not be included. Between 1996-2012 and 2015-2017, a total of 3928 
24-hours ABPM was performed. 
The following clinical data at the time of ABPM were retrieved: age, sex, body mass index (BMI), CV 
risk factors (smoking, dyslipidaemia, atrial fibrillation, diabetes mellitus, hypertension, sleep apnoea 
obstructive syndrome) and CV medication (renin-angiotensin inhibitors, calcium antagonists, 
diuretics, nitrates, statins, anti-platelet agents, anti-coagulation). Smoking was defined as ever 
smoking or never smoking. The CV risk factors were considered when written in the patient medical 
record. Basic blood chemistry (haemoglobin, leukocytes, fasting glycaemia, glycosylated haemoglobin, 
creatinine, fasting total cholesterol, fasting high-density-lipoprotein-cholesterol, fasting low-density-
lipoprotein-cholesterol, fasting triglycerides) and echocardiographic parameters were retrieved from 
electronic clinical records. All blood chemistry and echocardiographic data were retrieved from the 
normal clinical evaluation of the patients by their physician. Data retrieved was the closest possible in 
time from the ABPM date. The patients’ medical records were reviewed for further occurrence of CV 
events. 
The study was approved by the local ethical committee and all patients gave their informed consent. 
Twenty-four hour ABPM was performed during a working day with SpaceLabs 90207 (Space Labs Inc., 
Redmond, Washington, USA) as described earlier (217). The monitor was mounted on the 
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nondominant arm between 08:00 and 09:00 hours until 2007 and after that it was during the morning 
period and was removed 24 hours later. The proper calibration of ABPM was made according to 
guidelines in force. The patients were instructed to perform their usual daily activities and to report 
the time they went to bed and time they got up in the morning, as well all unusual events that 
happened during the day. Each patient was given a diary for the day which helped with this self-
reporting. BP was recorded every 20 minutes during the day (between 07:00 – 23:00 h) and every 30 
minutes at night (between 23:30-06:30 h). Only ABPM with over 85% of valid information was 
admitted. Pulse pressure was calculated as SBP minus diastolic BP (DBP). The nocturnal SBP fall (%) 
was calculated as 100 x (1-night SBP/day SBP ratio) and the nocturnal DBP fall (%) was calculated as 
100 x (1-awake DBP/day DBP ratio). The periods considered as representatives of the awake and night-
time resting BPs were the periods reported by the patient and registered in the device. Patients were 
classified by the nocturnal SBP fall as: extreme dippers (ED) if SBP fall ≥20%, dippers if nocturnal SBP 
fall was 10% or more and less than 20%, non-dippers if nocturnal SBP fall was between 0 and 9.9% 
and reverse dippers if nocturnal SBP fall was below 0%. The same equation and definitions were 
applied to DBP. Morning surge was defined by the mean nocturnal systolic values recorded in the first 
two hours upon waking up minus the mean nocturnal systolic values recorded immediately before, 
during and after the lowest SBP value of night-time.  
Follow-up was performed from ABPM until 2018. The presence or absence of CV events was assured 
by the examination of the patients’ medical records or phone call until the end of the follow-up period. 
CV events were diagnosed by the patient hospital physician or by medical records. In all cases, the 
diagnosis of CV events was objectively confirmed by an external expert who examined the patient’s 
records and diagnostic procedures. CV events were classified as fatal or nonfatal. Fatal events were 
subdivided in CV and non-CV. Cause of death was confirmed by medical records. If the cause of death 
was not confirmed, it was considered undetermined. CV events consisted of ischemic stroke, 
haemorrhagic stroke, transient ischemic attack, myocardial infarction, hospitalization by angina 
pectoris, coronary bypass, coronary angioplasty, carotid endarterectomy or surgery for PAD. For 
analysis, event by stroke, haemorrhagic stroke, ischemic stroke and transient ischemic attack were all 
considered integrating cerebrovascular disease; event by coronary disease, myocardial infarction, 
coronary revascularization and hospitalization for unstable angina were all considered coronary heart 
disease, and carotid endarterectomy and PAD were all considered other. The analysis was limited up 
to the first event after ABPM, considered the end of the follow-up. In the case of patients with more 
than one 24-hour ABPM between the two events, each ABPM was considered a separate entry for the 
database. 
Statistical analysis was performed using the SPSS software (version 25.0 Inc., Armonk, NY: IBM Corp). 
Missing values were excluded from the sample. Values of continued variables are presented as the 
mean + standard deviation (SD) or as percentages. Categorical variables were presented as 
percentages. Continuous variables were compared using non-parametric (Wilcoxon-Mann-Whitney 
test) and categorical using 2. Cox proportional hazards regression analysis was performed to evaluate 
the prognostic significance of the various BP measurements, after testing the proportional hazards 
assumption. The hazard ratio (HR) corresponds to the risk of having a total CV events, stroke and 
coronary events associated with a 1-SD increment or a 10 mmHg increment in BP values. In a 
multivariate cox regression analysis, the risk associated with a 1-SD increment in BP and to 10 mmHg 
increment was evaluated without and with adjustment for age, smoking, body mass index (BMI), 
diabetes, dyslipidaemia and office blood pressure. Adjustments for casual BP, 24-h BP, daytime BP and 
night-time BP were made when appropriated. Statistical tests for collinearity, with analysis of variance 
inflation factor, were conducted to assess the quality relationship among the predictor variables. Cox 
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analysis of tertiles of BP was performed. The receiver operating characteristic (ROC) curve was 
performed with evaluation of the area under the curve and the point of effectiveness, concerning 
sensibility and specificity was calculated. Kaplan Meier survival curves concerning cut-off values of BP 
thresholds were performed. Comparison was made based on log-rank. Cox regression analysis uni and 
multivariate was performed in several analyses. Statistical significance was considered for a p value < 
0.05. 
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6 General Results 
From the first cohort, 29 ABPM sere selected. Between 1997 and 2017 (excluding years 2013 until 
2015) were performed a total of 3928 ABPM, and 431 ABPM were selected from patients with 
previous CV event. These 460 ABPM were reviewed according to the inclusion and exclusion criteria, 
and 69 were excluded. 
6.1 Baseline characteristics of the population 
A total of 391 ABPM from 295 patients met the inclusion criteria. The first events were: 235 coronary 
events (from which 95 were revascularization procedures), 140 ischemic strokes, 11 haemorrhagic 
strokes, and five carotid and PAD procedures. The mean follow-up was 4.5 ± 5.2 (range 0.0-24.3), with 
a total of 1768 patient-years. Overall, medium age of 65.9 ± 10.4 years, 72.6% were men, 37.6% were 
diabetics, 19.2% had smoking habits and all had hypertension.  All patients were Caucasian. Baseline 
characteristics of the population are described in Table 13.  
No difference concerning BMI, diabetes, smoking or medication was found between the recurrent 
event group and the non-recurrent event. Atrial fibrillation was found in 11.5% of the total cohort, 
and 77.3% of the patients with atrial fibrillation was on anticoagulants. 
There were 93 recurrent CV events, none fatal, and 21 non-cardiovascular deaths. The recurrent 
events were 42 ischemic strokes, 38 coronary events (15 of which were coronary revascularization 
procedures), seven haemorrhagic strokes, five PAD surgeries and one carotid endarterectomy.  
Table 13 - Baseline characteristics of the population 
 All 
(n=391) 
No Event 
(n=298) 
With Event 
(n=93) 
p value 
Age (mean, years) 65.9 ± 10.4 66.5 ± 10.3 64.0 ± 10.6 0.085 
Male, n (%) 284 (72.6%) 214 (71.8%) 70 (75.3%) 0.514 
BMI (kg/m2) 28.3 ± 3.7 28.1 ± 3.5 29.0 ± 4.4 0.186 
Diabetes mellitus, n (%) 147 (37.6%) 111 (37.3%) 36 (38.7%) 0.321 
Smoking, n (%) 75 (19.2%) 55 (18.5%) 20 (21.5%) 0.514 
Dyslipidaemia, n (%) 318 (81.3%) 253 (84.9%) 65 (69.9%) 0.071 
Atrial Fibrillation, n (%) 45 (11.5%) 29 (9.7%) 16 (17.2%) 0.018 
Total Cholesterol (mg/dl) 164.1 ± 38.2 167.3 ± 37.7 152.4 ± 38.1 0.005 
Serum Creatinine (mg/dl) 1.14 ± 0.41 1.12 ± 0.38 1.24 ± 0.50 0.011 
Fasting Glycaemia 
(mg/dl) 
124.7 ± 45.1 123.9 ± 45.4 127.2 ± 44.4 0.420 
Echo TT – LA A (cm2) 22.4 ± 4.8 22.1 ± 4.6 24.4 ± 5.6 0.089 
Echo LVIDs (mm) 35.0 ± 9.8 33.9 ± 6.2 39.7 ± 17.9 0.583 
Echo LVPWD (mm) 10.9 ± 1.5 10.8 ± 1.4 11.6 ± 1.4 0.005 
ACEI/ARBs, n (%) 341 (87.2%) 269 (90.3%) 72 (77.4%) 0.144 
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 All 
(n=391) 
No Event 
(n=298) 
With Event 
(n=93) 
p value 
Diuretics, n (%) 215 (55.0%) 162 (54.4%) 53 (57.0%) 0.123 
Statins, n (%) 331 (85.7%) 260 (87.2%) 71 (76.3%) 0.574 
Anti-Platelets, n (%) 248 (63.4%) 201 (67.4%) 47 (50.5%) 0.046 
Anti-coagulants, n (%) 45 (11.5%) 30 (10.1%) 15 (16.1%) 0.047 
Office SBP (mmHg) 147.1 ± 24.1 145.9 ± 24.1 150.9 ± 23.7 0.080 
Office DBP (mmHg) 85.0 ± 14.5 83.6 ± 13.4 89.4 ± 16.6 0.009 
24 H SBP (mmHg) 129.2 ± 15.5 127.8 ± 15.2 133.7 ± 15.7 0.001 
24h DBP (mmHg) 72.8 ± 10.0 71.8 ± 9.3 76.1 ± 11.3 0.002 
24 h PP (mmHg) 56.6 ± 13.6 56.3 ± 13.7 58.0 ± 13.0 0.257 
24 h HR (ppm) 66.1 ± 9.8 65.8 ± 9.4 67.2 ± 11.2 0.161 
SD 24 h SBP (mmHg) 15.2 ± 3.9 15.1 ± 3.9 15.5 ± 3.9 0.452 
Daytime SBP (mmHg) 133.6 ± 15.9 132.2 ± 15.5 138.1 ± 16.3 0.001 
Daytime DBP (mmHg) 76.4 ± 10.6 75.3 ± 10.1 79.6 ± 11.4 0.001 
Daytime PP (mmHg) 57.4 ± 13.8 57.0 ±13.9 58.7 ± 13.4 0.275 
Daytime HR (ppm) 68.6 ± 10.8 68.3 ± 10.2 69.7 ± 12.6 0.252 
SD Daytime SBP (mmHg) 14.2 ± 4.1 14.1 ± 4.1 14.4 ± 3.9 0.644 
Night-Time SBP (mmHg) 121.4 ± 17.2 119.9 ± 17.1 126.2 ± 16.5 0.002 
Night-Time DBP (mmHg) 66.5 ± 10.1 65.5 ± 9.2 69.8 ± 12.0 0.006 
Night-time PP (mmHg) 55.1 ± 14.3 54.6 ± 14.6 56.9 ± 13.1 0.137 
Night-Time HR (ppm) 61.5 ± 9.3 61.2 ± 9.0 62.7 ± 10.0 0.104 
SD Night-time SBP 
(mmHg) 
12.3 ± 4.2 12.1 ± 4.2 12.7 ± 4.2 0.122 
Night-Time/Daytime of 
SBP (%) 
9.5 ± 10.2 9.8 ± 10.9 8.5 ± 7.6 0.274 
Night-Time/Daytime of 
DBP (%) 
12.9 ± 9.4 13.0 ± 9.8 12.5 ± 8.0 0.657 
Systolic morning surge 
(mmHg) 
23.4 ± 20.7 22.7 ± 21.2 25.6 ± 18.9 0.588 
ACEI - angiotensin converting enzyme inhibitors, ARB - angiotensin receptor blockers, BMI - body mass index, CI – confidence interval, DBP 
- diastolic blood pressure, Echo TT - transthoracic echocardiogram, h – hours, HR – heart rate, LA A - left auricular area, LVIDs - left ventricular 
internal diameter in systole, LVPWD - left ventricular posterior wall dimensions, PP - pulse pressure, SBP - systolic blood pressure 
Comparison between patients with and without recurrent events had no statistical difference 
concerning several risk factors: age, sex, diabetes, smoking and dyslipidaemia. Patients without 
recurrent event had higher total cholesterol and lower serum creatinine.  
51 
6.2 Research questions 
In this section, we structure the presentation of the results after each research question.  
6.2.1 “Does ABPM have any predictive value for recurrent cardiovascular disease?” and 
“Which ABPM variables have higher predictive value for recurrent cardiovascular 
events, if any”? 
Table 14 shows univariate analysis (and 95% confidence interval) of the population characteristics and 
ABPM variables in relation to total CV events. 
Table 14 - Univariate analysis of the population for total cardiovascular events  
 HR 
 
95% CI p value 
Age 1.031 1.009-1.053 0.006 
Gender 1.311 0.815-2.111 0.264 
BMI 1.045 0.987-1.107 0.132 
Diabetes 1.137 0.730-1.771 0.571 
Smoking 1.316 0.802-2.161 0.277 
Dyslipidaemia 1.640 0.908-2.965 0.101 
Atrial fibrillation 1.666 0.961-2.890 0.069 
Total cholesterol  0.987 0.979-0.996 0.006 
creatinine 1.165 10.634-2.139 0.623 
Fasting glycaemia 0.999 0.993-1.005 0.691 
Echo TT – LA A 1.037 0.963-1.117 0.339 
Echo LVIDs  0.987 0.964-1.011 0.276 
Echo LVPWD 1.393 1.055-1.841 0.020 
ACEI/ARBs 0.661 0.304-1.440 0.297 
Diuretics 1.131 0.707-1.812 0.607 
Statins 1.505 0.722-3.139 0.275 
Anti-platelets 0.887 0.564-1.394 0.602 
Office SBP 1.001 0.992-1.010 0.894 
Office DBP 0.995 0.980-1.010 0.494 
24h SBP 1.014 1.000-1.027 0.047 
24h DBP 1.001 0.980-1.023 0.913 
24 h PP 1.020 1.003-1.036 0.018 
24 h heart rate 1.010 0.989-1.032 0.339 
SD 24 h SBP 1.039 0.989-1.092 0.125 
Daytime SBP 1.015 1.002-1.029 0.024 
Daytime DBP 1.004 0.983-1.024 0.730 
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 HR 
 
95% CI p value 
Daytime PP 1-020 1-004-1.037 0.013 
Daytime heart rate 1.011 0.999-1.023 0.256 
SD Daytime SBP 1.029 0.982-1.078 0.231 
Night-Time SBP 1.011 0.999-1.023 0.068 
Night-Time DBP 1.004 0.984-1.024 0.715 
Night-time PP 1.017 1.002-1.033 0.026 
Night-time heart rate 1.009 0.987-1.032 0.412 
SD Night- time SBP 1.045 0.998-1.094 0.061 
Night-Time/Daytime of SBP 0.996 0.971-1.022 0.779 
Night-Time/Daytime of DBP 1.001 0.977-1.025 0.930 
Systolic morning surge 1.005 0.992-1.019 0.427 
ACEI - angiotensin converting enzyme inhibitors, ARB - angiotensin receptor blockers, BMI - body mass index, CI – confidence interval, h – 
hours; DBP - diastolic blood pressure, Echo TT - transthoracic echocardiogram, HR – hazard ratio; LA A - left auricular area, LVIDs - left 
ventricular internal diameter in systole, LVPWD - left ventricular posterior wall dimensions; PP - pulse pressure, SBP - systolic blood pressure  
 
In Table 15 is presented the multivariate Cox analysis of SBP and DBP, with further adjustments to 
other continuous ABPM variables in relation to total CV events 
Table 15 - Multivariate analysis of continuous blood pressure variables for total cardiovascular outcomes 
 HR (IC 95%)Ɏ HR (CI 95%) Ɏ 
and for 24 h 
DBP 
HR (CI 95%) Ɏ 
and for 
daytime DBP 
HR (CI 95%) Ɏ 
and for night-
time SBP 
HR (CI 95%) Ɏ 
and for night-
time DBP 
HR (CI 95%) Ɏ 
and for 
daytime SBP 
HR (CI 95%) Ɏ 
and for 24 h 
SBP 
24-hour 
SBP 
1.032  
(1.008-1.057)* 
1.021  
(0.993-1.050) 
 §  §  
Daytime 
SBP 
1.045  
(1.019-1.071)* 
 
1.034  
(1.004-1.064)** 
1.052  
(1.018-1.088)* 
  § 
Night-time 
SBP 
1.015  
(0.998-1.033) 
   
1.007  
(0.984-1.030) 
0.992  
(0.970-1.015) 
§ 
24-hour 
DBP 
1.055  
(1.011-1.100)** 
 §  §  
1.048  
(0.998-1.099) 
Daytime 
DBP 
1.064  
(1.022-1.107)* 
   
1.064  
(1.013-1.118)** 
1.054  
(1.008-1.102)** 
 
Night-time 
DBP 
1.029  
(0.997-1.062) 
§ 
1.000  
(0.961-1.039) 
1.026  
(0.984-1.069) 
   
CI – confident interval; DBP – diastolic blood pressure; h- hour; HR – hazard ratio; SBP – systolic blood pressure 
Ɏ adjusted for age, sex, BMI, diabetes, smoking status, dyslipidaemia and office BP 
* p<0.01; ** p<0.05 
§ High collinearity (≥ 4) 
 
In our study, 24-hour and daytime SBP, and 24-hour and daytime DBP significantly predicted total CV 
events. Daytime SBP and daytime DBP persisted significantly after further adjustment (daytime SBP 
adjusted for daytime DBP or night-time SBP; daytime DBP adjusted for night-time DBP or daytime 
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SBP). Night-time never showed significant increased risk, and 24-hour SBP and 24-hour DBP lost 
strength when adjusted respectively to 24-hour DBP and 24-hour SBP. Daytime variables provide 
additional predictive information over 24-hour and over night-time.  
Table 16 shows the hazard ratio associated with each 1-SD increment and 10 mmHg increment of BP. 
Analysing by 1 SD increment, 24-hours SBP significantly predicted CV events, but lost its significance 
when adjusted for 24-hour DBP. Daytime SBP significantly predicted CV events, adjusted for 
confounding factors, maintaining its significance when adjusted for daytime DBP and night-time SBP. 
For each SD increment, 24-hour and daytime SBP, 24-hour and daytime DBP significantly predicted 
risk for CV events, when adjusted for several confounders and office BP (model 2). After further 
adjustment, only daytime SBP and daytime DBP maintained significance.  
For each 10 mmHg increment, 24 hour SBP, daytime SBP, 24 hour DBP and daytime DBP were 
significant predictors of risk for CV events, when adjusted for several confounders (model 2). Daytime 
SBP and 24-hour DBP persisted significantly, even after further adjustment for night-time SBP and 24-
hour SBP (models 3b, 3e and 3d). Daytime SBP is more significant than night-time BP for total CV 
events in multivariate analysis. 
Table 16 - Multivariate analysis for total cardiovascular events by 1 SD increment and by 10 mmHg increment 
 Cardiovascular events 
(95% CI) 
Collinearity  Cardiovascular events 
(CI 95%) 
Collinearity 
Systolic BP HR  Systolic BP HR  
  1 SD office SBP   10 mmHg office SBP 
     Model 1 1.018 (0.821-1.262)         Model 1 0.998 (0.910-1.093)  
  1 SD 24 h SBP   10 mmHg 24 h SBP 
     Model 1 1.239 (1.000-1.535)*         Model 1 1.127 (0.988-1.287)  
     Model 2 1.456 (1.932-2.055)** 1.695        Model 2 1.258 (0.998-1.585) 1.849 
     Model 3a 1.239 (0.841-1.825) 2.215        Model 3a 1.115 (0.856-1.454) 2.628 
  1 SD daytime SBP     10 mmHg daytime SBP   
     Model 1 1.243 (1.020-1.515)**         Model 1 1.164 (1.026-1.319)**  
     Model 2 1.797 (1.255-2.572)* 2.031        Model 2 1.603 (1.248-2.057)* 2.051 
     Model 3b 1.575 (1.058-2.347)** 2.525        Model 3b 1.514 (1.136-2.018)* 2.793 
     Model 3e 1.845 (1.198-2.842)* 3.142        Model 3e 1.755 (1.279-2.409)* 3.754 
1 SD night-time SBP   10 mmHg night-time SBP 
     Model 1 1.180 (0.977-1.424)         Model 1 1.126 (0.999-1.269)  
     Model 2 1.243 (0.940-1.642) 1.360        Model 2 1.147 (0.966-1.361) 1.408 
     Model 3c 1.135 (0.815-1.580) 2.136        Model 3c 1.083 (0.880-1.334) 2.242 
     Model 3f 0.963 (0.687-1.349) 2.105        Model 3f 0.902 (0.725-1.123) 2.452 
Diastolic BP   Diastolic BP   
  1 SD casual DBP   10 mmHg casual DBP 
     Model 1 0.960 (0.782-1.179)         Model 1 0.926 (0.798-1.074)  
  1 SD 24 h DBP   10 mmHg 24 h DBP 
     Model 1 1.032 (0.844-1.262)         Model 1 1.032 (0.844-1.262)  
     Model 2 1.545 (1.086-2.199)** 2.284        Model 2 1.545 (1.086-2.199)** 2.284 
     Model 3d 1.486 (0.993-2.224) 2.977        Model 3d 1.529 (1.032-2.265)** 3.055 
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(Continued from last page) 
 Cardiovascular events 
(95% CI) 
Collinearity  Cardiovascular events 
(CI 95%) 
Collinearity 
Diastolic BP   Diastolic BP   
  1 SD daytime DBP   10 mmHg daytime DBP 
     Model 1 1.040 (0.838-1.290)         Model 1 1.025 (0.844-1.244)  
     Model 2 1.638 (1.139-2.357)* 2.411        Model 2 1.566 (1.094-2.240)** 2.649 
     Model 3 f 1.505 (1.021-2.219)** 2.818        Model 3 f 1.386 (0.940-2.045) 3.379 
     Model 3 c 1.607 (1.051-2.456)** 3.369        Model 3 c 1.515 (0.997-2.301) 3.719 
  1 SD night-time DBP   10 mmHg night-time DBP 
     Model 1 1.019 (0.837-1.241)         Model 1 1.019 (0.837-1.241)  
     Model 2 1.254 (0.926-1.698) 1.610        Model 2 1.254 (0.926-1.698) 1.610 
     Model 3 e 1.197 (0.837-1.711) 2.477        Model 3 e 1.195 (0.833-1.715) 2.439 
     Model 3 b 1.031 (0.728-1.462) 2.250        Model 3 b 1.054 (0.746-1.489) 2.260 
CI – confident interval; DBP – diastolic blood pressure; h- hour; HR – hazard ratio; SBP – systolic blood pressure; SD- standard deviation 
   Model 1 – without adjustment 
   Model 2 – after adjustment for age, sex, BMI, smoking status, dyslipidaemia, diabetes, and office BP 
   Model 3 – as model 2 plus adjustment for: (a) 24 h DBP; (b) daytime DBP; (c) night-time DBP; (d)  
24 h SBP; (e) night-time SBP; (f) daytime SBP 
Significance of hazard ratios: *p<0.01, **p<0.05 
 
• Analysis of the subgroup with coronary first event 
We performed an analysis of the subgroup with coronary disease events including coronary 
revascularization, comparing the ones with recurrent event with those without. From a total of 235 
ABPM with coronary event as first event, 61 had recurrent event.  The follow-up was 4.5 ± 5.1 years. 
esults are presented in Table 17. 
Table 17 - Baseline characteristics of the subgroup with coronary event (first event) 
 All 
(n=235) 
No Event 
(n=174) 
With Event 
(n=61) 
p value 
Age (mean, years) 66.8 ± 10.3 67.7 ± 10.4 64.3 ± 9.5 0.022 
Male, n (%) 195 (83.0%) 139 (79.9%) 56 (91.8%) 0.033 
BMI (kg/m2) 28.3 ± 3.6 28.1 ± 3.5 28.6 ± 4.0 0.707 
Diabetes, n (%) 101 (43.0%) 75 (43.1%) 26 (42.6%) 0.551 
Smoking, n (%) 54 (23.0%) 35 (20.1%) 19 (31.1%) 0.078 
Dyslipidaemia, n (%) 206 (87.7%) 158 (90.8%) 48 (78.7%) 0.543 
Atrial Fibrillation, n (%) 28 (11.9%) 21 (12.1%) 7 (11.5%) 0.881 
Total Cholesterol (mg/dl) 155.5 ± 33.8 159.3 ± 35.1 140.9 ± 23.5 0.015 
Serum Creatinine (mg/dl) 1.22 ± 0.46 1.20 ± 0.43 1.31 ± 0.57 0.072 
Fasting Glycaemia 
(mg/dl) 
134,8 ± 50.9 136.3 ± 52.2 130.9 ± 48.0 0.750 
Echo TT – LA A (cm2) 22.8 ± 4.5 22.7 ± 4.5 23.3 ± 4.4 0.729 
Echo LVIDs (mm) 36.6 ± 11.4 34.9 ± 5.8 42.4 ± 20.7 0.802 
Echo LVPWD (mm) 10.7 ± 1.4 10.6 ± 1.4 11.1 ± 1.4 0.207 
ACEI/ARBs, n (%) 211, (89.8%) 161 (92.5%) 50 (82.0%) 0.726 
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 All 
(n=235) 
No Event 
(n=174) 
With Event 
(n=61) 
p value 
Diuretics, n (%) 136 (57.9%) 96 (55.2%) 40 (65.6%) 0.015 
Statins, n (%) 213 (90.6%) 161 (92.5%) 52 (82.5%) 0.690 
Anti-Platelets, n (%) 172 (73.2%) 140 (80.5%) 32 (52.5%) 0.001 
Office SBP (mmHg) 148.0 ± 22.9 146.9 ± 22.2 151.2 ± 24.4 0.290 
Office DBP (mmHg) 83.1 ± 13.9 81.5 ± 12.9 87.7 ± 15.7 0.010 
24 H SBP (mmHg) 129.1 ± 14.8 127.1 ± 13.9 134.7 ± 16.1 0.001 
24h DBP (mmHg) 71.0 ± 9.1 69.6 ± 8.1 74.9 ± 10.6 0.001 
24 h PP (mmHg) 58.4 ± 13.6 57.7 ± 13.6 60.5 ± 13.5 0.191 
24 h HR (ppm) 63.7 ± 9.1 63.4 ± 8.2 64.5 ± 11.2 0.468 
SD 24 h SBP (mmHg) 15.1 ± 4.0 15.0 ± 4.0 15.4 ± 4.1 0.561 
Daytime SBP (mmHg) 133.3 ± 15.5 131.4 ± 14.4 138.8 ± 17.0 0.002 
Daytime DBP (mmHg) 74.3 ± 9.8 73.0 ± 9.1 78.1 ± 10.8 0.001 
Daytime PP (mmHg) 59.3 ± 13.9 58.6 ± 13.9 61.3 ± 13.8 0.200 
Daytime HR (ppm) 65.8 ± 9.8 65.5 ± 8.7 66.5 ± 12.4 0.583 
SD Daytime SBP (mmHg) 14.2 ± 4.2 14.1 ± 4.2 14.4 ± 4.1 0.750 
Night-Time SBP (mmHg) 121.7 ± 16.5 119.7 ± 16.1 127.4 ± 16.2 0.002 
Night-Time DBP (mmHg) 65.1 ± 9.3 63.7 ± 8.0 69.1 ± 11.3 0.003 
Night-time PP (mmHg) 57.0 ± 14.2 56.2 ± 14.3 59.3 ± 13.5 0.150 
Night-Time HR (ppm) 59.9 ± 8.8 59.7 ± 8.4 60.7 ±9.9 0.384 
SD Night-time SBP 
(mmHg) 
12.0 ± 4.0 11.8 ± 4.0 12.7 ± 4.15 0.111 
Night-Time/Daytime of 
SBP (%) 
9.0 ± 10.2 9.4 ± 10.9 7.9 ± 7.7 0.311 
Night-Time/Daytime of 
DBP (%) 
12.5 ± 10.31 12.9 ± 10.9 11.5 ± 8.3 0.357 
Systolic morning surge 
(mmHg) 
24.3 ± 20.8 23.8 ± 20.7 25.4 ± 21.1 0.489 
ACEI - angiotensin converting enzyme inhibitors, ARB - angiotensin receptor blockers, BMI - body mass index, CI – confidence interval, DBP 
- diastolic blood pressure, Echo TT - transthoracic echocardiogram, h – hours, HR – heart rate, LA A - left auricular area, LVIDs - left ventricular 
internal diameter in systole, LVPWD - left ventricular posterior wall dimensions, PP - pulse pressure, SBP - systolic blood pressure, SD – 
standard deviation 
The subgroup of patients with coronary first event were younger, with lower serum fasting cholesterol 
and with predominance of male gender. They also had higher prevalence of use of diuretics and a 
significant lower use of anti-platelets. In this subgroup, systolic and diastolic BP (24-hour, daytime and 
night-time) were significantly higher in the patients with recurrent event versus the non-recurrent 
event patients. 
The univariate Cox analysis is presented in Table 18. 
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Table 18 - Univariate analysis for recurrent cardiovascular events (subgroup with first coronary event) 
 HR 95% CI p value 
Office SBP 1.003 0.991-1.015 0.601 
Office DBP 0.999 0.980-1.018 0.904 
24h SBP 1.018 1.001-1.036 0.042 
24h DBP 1.005 0.977-1.034 0.737 
24 h PP 1.026 1.005-1.047 0.015 
24 h heart rate 1.016 1.987-1.045 0.283 
SD 24 h SBP 1.034 0.980-1.092 0.224 
Daytime SBP 1.018 1.001-1.035 0.041 
Daytime DBP 1.003 0.977-1.030 0.812 
Daytime PP 1.026 1.006-1.047 0.013 
Daytime heart rate 1.018 0.993-1.045 0.164 
SD Daytime SBP 1.029 0.979-1.081 0.264 
Night-Time SBP 1.016 0.999-1.032 0.062 
Night-Time DBP 1.010 0.983-1.038 0.486 
Night-time PP 1.021 1.002-1.042 0.034 
Night-time heart rate 1.007 0.978-1.037 0.633 
SD Night- time SBP 1.049 0.991-1.111 0.098 
Night-Time/Daytime of SBP 0.995 0.965-1.026 0.752 
Night-Time/Daytime of DBP 0.993 0.965-1.022 0.620 
Systolic morning surge 1.003 0.988-1.019 0.666 
CI – confident interval; DBP – diastolic blood pressure; h- hour; HR – hazard ratio; PP – pulse pressure; SBP – systolic blood pressure; SD – 
standard deviation 
 
In the univariate analysis only 24-hour SBP and daytime SBP persisted with significant risk. 
• Analysis of the subgroup with cerebrovascular event as first event 
The analysis of the subgroup with stroke as first event, evaluated 151 patients and we performed the 
comparison between the group with recurrent event and the group without recurrent event. The 
follow-up was of 4.6 ± 5.3 years, and there were 32 recurrent events. 
In Table 19 we show the baseline characteristics of this subgroup. 
Table 19 - Baseline characteristics of the subgroup with cerebrovascular event (first event) 
 All 
(n=151) 
No Event 
(n=119) 
With Event 
(n=32) 
p value 
Age (mean, years) 64.5 ± 10.5 64.9 ± 9.9 63.3 ± 12.5 0.753 
Male, n (%) 85 (56.3%) 71 (59.7%) 14 (43.8%) 0.107 
BMI (kg/m2) 28.5 ± 3.9 28.1 ± 3.5 29.8 ± 5.1 0.110 
Diabetes, n (%) 45 (29.8%) 35 (29.4%) 10 (31.3%) 0.537 
Smoking, n (%) 18 (11.9%) 17 (14.3%) 1 (3.1%) 0.084 
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 All 
(n=151) 
No Event 
(n=119) 
With Event 
(n=32) 
p value 
Dyslipidaemia, n (%) 108 (71.5%) 91 (76.5%) 17 (53.1%) 0.038 
Atrial Fibrillation, n (%) 16 (10.6%) 7 (5.9%) 9 (28.1%) 0.000 
Total Cholesterol (mg/dl) 179.0 ± 41.1 181.3 ± 38.5 171.1 ± 49.3 0.211 
Serum Creatinine (mg/dl) 1.02 ± 0.3 1.00 ± 0.27 1.10 ± 0.31 0.131 
Fasting Glycaemia 
(mg/dl) 
114.1 ± 35.8 111.8 ± 34.5 122.6 ± 39.9 0.343 
Echo TT – LA A (cm2) 21.8 ± 5.31 21.1 ± 4.6 26.6 ± 7.2 0.069 
Echo LVIDs (mm) 32.6 ± 6.4 32.6 ± 6.7 33.2 ± 4.1 0.324 
Echo LVPWD (mm) 11.2 ± 1.4 11.0 ± 1.4 12.4 ± 1.1 0.003 
ACEI/ARBs, n (%) 126 (83.4%) 104 (87.4%) 22 (68.8%) 0.069 
Diuretics, n (%) 78 (51.7%) 65 (54.6%) 13 (40.6%) 0.372 
Statins, n (%) 114 (75.5%) 95 (79.8%) 19 (59.4%) 0.680 
Anti-Platelets, n (%) 73 (48.3%) 58 (48.7%) 15 (46.9%) 0.827 
Anti-coagulants, n (%) 20 (13.2%) 12 (10.1%) 8 (25.0%) 0.026 
Office SBP (mmHg) 146.3 ± 25.9 145.3 ± 26.6 150.1 ± 22.6 0.203 
Office DBP (mmHg) 88.2 ± 14.8 87.0 ± 13.6 92.8 ± 18.2 0.225 
24 h SBP (mmHg) 129.7 ± 16.6 129.1 ± 16.9 131.9 ± 15.3 0.306 
24 h DBP (mmHg) 75.7 ± 10.7 75.0 ± 10.2 78.3 ± 12.5 0.280 
24 h PP (mmHg) 54.0 ± 13.2 54.3 ± 13.8 52.9 ± 10.5 0.798 
24 h HR (ppm) 69.6 ± 9.6 68.9 ± 9.5 72.3 ± 9.6 0.067 
SD 24 h SBP (mmHg) 15.4 ± 3.7 15.3 ± 3.7 15.7 ± 3.7 0.579 
Daytime SBP (mmHg) 134.4 ± 16.7 133.7 ± 17.1 137.0 ± 15.0 0.207 
Daytime DBP (mmHg) 79.6 ± 11.5 78.8 ± 10.8 82.9 ± 11.9 0.12 
Daytime PP (mmHg) 54.8 ± 13.3 55.0 ± 13.8 53.7 ± 11.2 0.75 
Daytime HR (ppm) 72.8 ± 10.7 72.1 ± 10.5 75.7 ± 10.8 0.099 
SD Daytime SBP (mmHg) 14.1 ± 3.8 14.1 ± 3.9 14.3 ± 3.7 0.772 
Night-Time SBP (mmHg) 121.2 ± 18.1 120.5 ± 18.5 123.8 ± 17.0 0.428 
Night-Time DBP (mmHg) 68.9 ± 10.9 68.2 ± 10.0 71.2 ± 13.4 0.433 
Night-time PP (mmHg) 52.5 ± 14.1 52.5 ± 14.8 52.3 ± 10.9 0.79 
Night-Time HR (ppm) 63.8 ± 9.04 63.0 ± 8.9 66.6 ± 9.2 0.043 
SD Night-time SBP 
(mmHg) 
12.6 ± 4.3 12.6 ± 4.4 12.7 ± 4.2 0.542 
Night-Time/Daytime of 
SBP (%) 
10.2 ± 10.2 10.4 ± 10.9 9.6 ± 7.4 0.745 
Night-Time/Daytime of 
DBP (%) 
13.4 ± 7.8 13.1 ± 7.9 14.4 ± 7.2 0.447 
Systolic morning surge 
(mmHg) 
21.6 ± 20.6 20.6 ± 22.0 25.9 ± 12.3 0.54 
ACEI - angiotensin converting enzyme inhibitors, ARB - angiotensin receptor blockers, BMI - body mass index, , CI – confidence interval, DBP 
- diastolic blood pressure, Echo TT - transthoracic echocardiogram, h – hours, HR – heart rate, LA A - left auricular area, LVIDs - left ventricular 
internal diameter in systole, LVPWD - left ventricular posterior wall dimensions, PP - pulse pressure, SBP - systolic blood pressure 
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In the subgroup with first event stroke, patients with recurrent event had higher prevalence of atrial 
fibrillation and similar level of anti-coagulation. In the analysis of ABPM variables, only night-time 
heart rate was statistically different between the recurrent event group and those without recurrent 
event. 
The univariate Cox analysis of the ABPM variables showed no statistical difference in any of the 
variables (Table 20). 
Table 20 - Univariate analysis for recurrent cardiovascular events (subgroup with first cerebrovascular event) 
 HR 
 
95% CI p value 
Office SBP 0.996 0.981-1.012 0.658 
Office DBP 0.991 0.965-1.018 0.527 
24h SBP 1.005 0.983-1.028 0.649 
24h DBP 0.997 0962-1.034 0.887 
24 h PP 1.005 0.977-1.034 0.733 
24 h heart rate 1.022 0.985-1.062 0.248 
SD 24 h SBP 1.076 0.967-1.198 0.181 
Daytime SBP 1.011 0.988-1.034 0.364 
Daytime DBP 1.008 0.972-1.045 0.660 
Daytime PP 1.007 0.979-1.036 0.636 
Daytime heart rate 1.021 0.987-1.056 0.221 
SD Daytime SBP 1.042 0.936-1.161 0.454 
Night-Time SBP 1.004 0.985-1.023 0.711 
Night-Time DBP 0.996 0.964-1.029 0.808 
Night-time PP 1.007 0.980-1.034 0.625 
Night-time heart rate 1.025 0.987-1.066 0.203 
SD Night- time SBP 1.043 0.962-1.131 0.309 
Night-Time/Daytime of SBP 1.008 0.965-1.052 0.734 
Night-Time/Daytime of DBP 1.026 0.982-1.071 0.250 
Systolic morning surge 1.010 0.982-1.039 0.467 
CI – confident interval; DBP – diastolic blood pressure; h- hour; HR – hazard ratio; PP – pulse pressure; SBP – systolic blood pressure; SD – 
standard deviation 
6.2.2 “Will the limits of BP that best predict the first CV events be identical to those that 
predict the second events?” 
We studied SBP and DBP (24-hour, daytime and night-time) pattern, and divided each variable in 
tertiles of value of BP (Table 21). The univariate Cox analysis of each tertile showed unadjusted higher 
risk for 24-hour SBP ≥ 135 mmHg, night-time SBP (between 115-127 mmHg) and night-time DBP 
(between 62-70 mmHg).  
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Table 21 - Tertiles of systolic blood pressure and diastolic blood pressure in relation to risk of total cardiovascular events 
 HR 95% CI 
24 h SBP (≤ 123 mmHg) 
24 h SBP (124-134 mmHg) 
24 h SBP (≥ 135 mmHg) 
ref 
1.748 
1.823 
 
0.992-3.081 
1.017-3.271* 
Daytime SBP (≤ 127 mmHg) 
Daytime SBP (128-137 mmHg) 
Daytime SBP (≥ 138 mmHg) 
ref 
1.436 
1.722 
 
0.821-2.512 
0.992-2.990 
Night-time SBP (≤ 114 mmHg) 
Night-time SBP (115-127 mmHg) 
Night-time SBP (≥ 128 mmHg) 
ref 
1.767 
1.567 
 
1.036-3.013* 
0.916-2.680 
24 h DBP (≤ 67 mmHg) 
24 h DBP (68-77 mmHg) 
24 h DBP (≥ 78 mmHg) 
ref 
0.789 
0.833 
 
0.456-1.364 
0.501-1.384 
Daytime DBP (≤ 71 mmHg) 
Daytime DBP (72-81 mmHg) 
Daytime DBP (≥ 82 mmHg) 
ref 
1.048 
0.996 
 
0.608-1.807 
0.592-1.676 
Night-time DBP (≤ 61 mmHg) 
Night-time DBP (62-70 mmHg) 
Night-time DBP (≥ 71 mmHg) 
ref 
0.490 
0.818 
 
0.279-0.860* 
0.503-1.330 
CI – confidence interval, DBP – diastolic blood pressure, h – hours, HR – hazard ratio, SBP – systolic blood pressure  
*p<0.05 
 
The receiver operating characteristic (ROC) curve of SBP 24 hours with an area under the curve (AUC) 
of 0.614 was analysed for the best value of effectiveness, concerning both sensibility and specificity, 
for recurrent event risk prediction, which was 125 mmHg (82% sensitivity, 46% specificity). We 
evaluated the ROC curve for daytime SBP (AUC 0.613) and night-time SBP (AUC 0.604) and the best 
cut-offs values were, respectively, 131 mmHg (73% sensitivity, 49% specificity) and 112 mmHg 
(sensitivity 85%, specificity 33%). The Kaplan Meier survival curves were applied to these cut-offs and 
compared to the established guidelines ABPM cut-offs of diagnosis of hypertension (see The survival 
curve of patients divided by mean 24-hour SBP < 130 mmHg and ≥ 130 mmHg, daytime < 135 mmHg 
and ≥ 135 mmHg and night-time < 120 mmHg and ≥ 120 mmHg, had respectively log-ranks of 0.093, 
0.138 and 0.411. The survival curves using the thresholds of 125 mmHg for 24-hour SBP and 131 mmHg 
for daytime SBP showed a log-rank of 0.004 and 0.007, respectively. 
Figure 4). 
The survival curve of patients divided by mean 24-hour SBP < 130 mmHg and ≥ 130 mmHg, daytime < 
135 mmHg and ≥ 135 mmHg and night-time < 120 mmHg and ≥ 120 mmHg, had respectively log-ranks 
of 0.093, 0.138 and 0.411. The survival curves using the thresholds of 125 mmHg for 24-hour SBP and 
131 mmHg for daytime SBP showed a log-rank of 0.004 and 0.007, respectively. 
60 
Figure 4 - Kaplan Meier survival curves of different systolic blood pressure thresholds for total cardiovascular events 
  
 
 
 
 
The Cox regression analysis of these thresholds is showed in Table 22 in comparison with the current 
established guidelines cut-offs of 130 mmHg, 135 mmHg and 120 mmHg for mean 24-hour SBP, mean 
daytime SBP and mean night-time SBP, respectively. The threshold of 125 mmHg for mean 24-hour 
SBP and 131 mmHg for mean daytime SBP, were statistically significant, when adjusted for age, sex, 
body mass index, diabetes, dyslipidaemia, smoking and office SBP. 
Log-rank 0.004 Log-rank 0.093 
Log-rank 0.007 Log-rank 0.138 
Log-rank 0.079 Log-rank 0.411 
61 
Table 22 - Analysis of different systolic blood pressure thresholds and hazard risk for recurrent cardiovascular events 
 HR 
(unadjusted) 
 
p value HR * 95% CI p value 
24 h SBP (130 mmHg) 
24 h SBP (125 mmHg) 
1.417 
2.130 
0.095 
0.005 
1.604 
2.957 
0.912-2.823 
1.500-5.827 
0.101 
0.002 
Daytime SBP (135 mmHg) 
Daytime SBP (131 mmHg) 
1.360 
1.852 
0.140 
0.008 
1.713 
2.626 
0.972-3.019 
1.402-4.917 
0.063 
0.003 
Night-time SBP (120 mmHg) 
Night-time SBP (112 mmHg) 
1.189 
1.660 
0.412 
0.082 
1.218 
1.807 
0.725-2.046 
0.902-3.620 
0.456 
0.095 
 * adjusted for age, sex, body mass index, diabetes, dyslipidaemia, smoking, and office SBP 
CI – confident interval; DBP – diastolic blood pressure; HR – hazard ratio; SBP – systolic blood pressure 
6.2.3 “ABPM prediction values for recurrent cardiovascular events are they different 
between distinct age groups?”  
In our sample, mean age is 65.9 years and median 65 years. We divided our sample in patients under 
65 years old, and above 65 years old, and studied their characteristics and ABPM variables, to find if 
they would be more associated to risk in a given age.  
There were 179 patients < 65 years, and 212 with age ≥ 65 years. Patients < 65 years old had 50 CV 
events, over a mean follow-up of 6.3 ± 6.3 years (medium 3.6 years). Patients ≥ 65 years had 43 events 
over a mean follow up of 3.0 ± 3.2 years (medium 1.9 years). 
In Table 23 we compared baseline characteristics between patients under 65 years and patients ≥ 65 
years.   
Table 23 – Baseline characteristics of patients <65 years and ≥ 65 years 
 All 
(n=391) 
< 65 years 
(n=179) 
≥ 65 years 
(n=212) 
p value 
Age (mean, years) 65.9 ± 10.4 56.7 ± 6.1 73.6 ± 6.0 0.000 
Male, n (%) 284 (72.6%) 143 (79.9%) 141 (66.5%) 0.003 
BMI (kg/m2) 28.3 ± 3.7 29.0 ± 4.0 27.8 ± 3,4 0.008 
Diabetes mellitus, n (%) 147 (37.6%) 60 (33.5%) 87 (41%) 0.199 
Smoking, n (%) 75 (19.2%) 50 (27.9%) 25 (11.8%) 0.000 
Dyslipidaemia, n (%) 318 (81.3%) 133 (74.3%) 185 (87.3%) 0.002 
Atrial Fibrillation, n (%) 45 (11.5%) 12 (6.7%) 33 (15.6%) 0.009 
Total Cholesterol (mg/dl) 164.1 ± 38.2 167.8 ± 43.5 161.4 ± 33.6 0.489 
Serum Creatinine (mg/dl) 1.14 ± 0.41 1.08 ± 0.26 1.19 ± 0.49 0.392 
Fasting Glycaemia 
(mg/dl) 
124.7 ± 45.1 126.4 ± 52.1 122.9 ± 36.6 0.433 
Echo TT – LA A (cm2) 22.4 ± 4.8 21.9 ± 4.5 22.6 ± 5.0 0.231 
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 All 
(n=391) 
< 65 years 
(n=179) 
≥ 65 years 
(n=212) 
p value 
Echo LVIDs (mm) 35.0 ± 9.8 37.2 ± 13.1 33.5 ± 6.5 0.562 
Echo LVPWD (mm) 10.9 ± 1.5 10.9 ± 1.6 10.9 ± 1.4 0.636 
ACEI/ARBs, n (%) 341 (87.2%) 152 (84.9%) 189 (89.2%) 0.635 
Diuretics, n (%) 215 (55.0%) 98 (54.7%) 117 (55.2%) 0.743 
Statins, n (%) 331 (84.7%) 140 (78.2%) 191 (90.1%) 0.002 
Anti-Platelets, n (%) 248 (63.4%) 106 (59.2%) 142 (67.0%) 0.227 
Anti-coagulants, n (%) 45 (11.5%) 11 (6.1%) 34 (16.0%) 0.003 
Office SBP (mmHg) 147.1 ± 24.1 144.7 ±24.1 149.0 ± 24.0 0.037 
Office DBP (mmHg) 85.0 ± 14.5 90.7 ± 14.7 80.2 ± 12.4 0.000 
24 H SBP (mmHg) 129.2 ± 15.5 128.9 ± 16.7 129.4 ± 14.5 0.377 
24h DBP (mmHg) 72.8 ± 10.0 78.0 ± 9.8 68.4 ± 7.8 0.000 
24 h PP (mmHg) 56.6 ± 13.6 51.1 ± 12.5 61.1 ± 12.8 0.000 
24 h HR (ppm) 66.1 ± 9.8 68.9 ± 10.2 63.7 ± 8.9 0.000 
SD 24 h SBP (mmHg) 15.2 ± 3.9 14.5 ± 3.5 15.8 ± 4.1 0.002 
Daytime SBP (mmHg) 133.6 ± 15.9 133.2 ± 16.8 133.9 ± 15.2 0.363 
Daytime DBP (mmHg) 76.4 ± 10.6 81.6 ± 10.4 71.9 ± 8.6 0.000 
Daytime PP (mmHg) 57.4 ± 13.8 51.8 ± 12.6 62.0 ± 13.0 0.000 
Daytime HR (ppm) 68.6 ± 10.81 71.6 ± 11.3 66.1 ± 9.9 0.000 
SD Daytime SBP (mmHg) 14.2 ±4.1 13.3 ± 3.5 14.9 ± 4.4 0.000 
Night-Time SBP (mmHg) 121.4 ± 17.2 120.6 ± 18.1 122.0± 16.4 0.236 
Night-Time DBP (mmHg) 66.5 ± 10.1 71.1 ± 10.4 62.6 ± 8.0 0.000 
Night-time PP (mmHg) 55.1 ± 14.3 49.8 ± 12.9 59.5 ± 14.0 0.000 
Night-Time HR (ppm) 61.5 ± 9.3 63.8 ± 9.2 59.6 ± 9.0 0.000 
SD Night-time SBP 
(mmHg) 
12.3 ± 4.2 11.6 ± 4.0 12.8 ± 4.3 0.004 
Night-Time/Daytime of 
SBP (%) 
9.5 ± 10.2 9.5 ± 7.6 9.5 ± 12.0 0.769 
Night-Time/Daytime of 
DBP (%) 
12.9 ± 9.4 12.7 ± 8.4 13.0 ± 10.2 0.796 
Systolic morning surge 
(mmHg) 
23.4 ± 20.7 23.9 ± 16.3 22.8 ± 24.06 0.902 
ACEI - angiotensin converting enzyme inhibitors, ARB - angiotensin receptor blockers, BMI - body mass index, CI – confidence interval, DBP 
- diastolic blood pressure, Echo TT - transthoracic echocardiogram, h – hours, HR – heart rate, LA A - left auricular area, LVIDs - left ventricular 
internal diameter in systole, LVPWD - left ventricular posterior wall dimensions; PP - pulse pressure, SBP - systolic blood pressure 
 
The two populations have major differences, not just because they are different age groups, but also 
in most of comorbidities. Patients under 65 years have higher prevalence of men, higher BMI and 
dyslipidaemia and higher prevalence of patients with smoking habits. Although the group ≥ 65 years 
had 41% of diabetics, the comparison between the two groups was not statically significant. Older 
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patients had a much higher prevalence of atrial fibrillation. There was no difference between groups 
concerning medication, except for statins. Although patients under 65 years old had a higher 
prevalence of dyslipidaemia, had also a smaller prevalence of use of statins.  
In the group of patients < 65 years old, the mean 24-hour SBP for those with recurrent event versus 
no recurrent event was 135.3 ± 16.9 mmHg versus 126.4 ± 15.9 (p 0.000). In the group of patients ≥ 
65 years old, the mean 24-hour SBP for those with recurrent event versus no recurrent event was 
131.9 ± 14.3 versus 128.8 ± 14.5 (p 0.309). 
We performed univariate and multivariate Cox analysis, adjusted for age, gender, diabetes, smoking 
status, dyslipidaemia and office BP. Table 24 shows the HR of the relation of several ABPM variables 
and the risk of total CV outcome. 
Table 24 - Univariate and multivariate analysis of patients < 65 years and ≥ 65 years old for total cardiovascular events 
  Univariate 
HR (CI 95%)  
Multivariate*  
HR (CI 95%) 
p value 
Office SBP  
< 65 years 1.000 (0.988-1.012)   
≥ 65 years 0.998 (0.984-1.012)   
Office DBP 
< 65 years 0.994 (0.973-1.015)   
≥ 65 years 1.011 (0.985-1.037)   
24h SBP 
< 65 years 1.021 (1.004-1.039) 1.066 (1.026-1.107) 0.001 
≥ 65 years 1.000 (0.980-1.021) 1.010 (0.976-1.046) 0.565 
24h DBP 
< 65 years 1.022 (0.991-1.054) 1.065 (1.014-1.118) 0.011 
≥ 65 years 1.005 (0.967-1.044) 1.021 (0.969-1.076) 0.440 
24 h heart rate 
< 65 years 1.017 (0.989-1.046) 1.007 (0.971-1.045) 0.714 
≥ 65 years 1.022 (0.986-1.059) 1.010 (0.971-1.050) 0.631 
SD 24 h SBP 
< 65 years 0.986 (0.914-1.075) 0.950 (0.848-1.063) 0.371 
≥ 65 years 1.048 (0.985-1.116) 1.074 (0.984-1.172) 0.111 
Daytime SBP 
< 65 years 1.020 (1.003-1.038) 1.072 (1.030-1.116) 0.001 
≥ 65 years 1.006 (0.986-1.027) 1.029 (0.992-1.068) 0.122 
Daytime DBP 
< 65 years 1.017 (0.987-1.048) 1.053 (1.007-1.102) 0.023 
≥ 65 years 1.019 (0.984-1.055) 1.042 (0.994-1.094) 0.089 
Daytime heart rate 
< 65 years 1.017 (0.992-1.042) 1.009 (0.978-1.040) 0.589 
≥ 65 years 1.021 (0.988-1.055) 1.008 (0.971-1.046) 0.682 
SD Daytime SBP 
< 65 years 0.994 (0.913-1.083) 0.917 (0.808-1.040) 0.178 
≥ 65 years 1.023 (0.963-1.086) 1.017 (0.934-1.108) 0.691 
Night-Time SBP 
< 65 years 1.021 (1.006-1.037) 1.048 (1.017-1.079) 0.002 
≥ 65 years 0.996 (0.978-1.014) 0.996 (0.971-1.021) 0.742 
Night-Time DBP 
< 65 years 1.028 (1.001-1.056) 1.059 (1.017-1.103) 0.006 
≥ 65 years 0.987 (0.950-1.025) 0.989 (0.942-1.038) 0.658 
Night-time heart rate 
< 65 years 1.013 (0.982-1.045) 1.009 (0.968-1.051) 0.673 
 1.024 (0.990-1.060) 1.018 (0.981-1.056) 0.354 
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  Univariate 
HR (CI 95%)  
Multivariate*  
HR (CI 95%) 
p value 
SD Night- time SBP 
< 65 years 1.028 (0.959-1.102) 1.000 (0.915-1.093) 0.997 
≥ 65 years 1.048 (0.983-1.117) 1.091 (1.006-1.183) 0.036 
Night-Time/Daytime 
of SBP 
< 65 years 0.969 (0.934-1.006) 0.971 (0.924-1.021) 0.255 
≥ 65 years 1.017 (0.990-1.045) 1.021 (0.992-1.052) 0.156 
Night-Time/Daytime 
of DBP 
< 65 years 0.972 (0.940-1.004) 0.981 (0.942-1.021) 0.336 
≥ 65 years 1.028 (1.003-1.054) 1.030 (1.003-1.058) 0.029 
Systolic morning 
surge 
< 65 years 1.004 (0.985-1.023) 0.997 (0.976-1.018) 0.767 
≥ 65 years 1.006 (0.988-1.024) 1.010 (0.989-1.031) 0.372 
* adjusted for age, gender, diabetes, smoking status, dyslipidaemia, BMI, office BP 
CI – confident interval; DBP – diastolic blood pressure; h – hour; HR – hazard ratio; SBP – systolic blood pressure; SD- standard deviation  
 
The group < 65 years had significant HR in multivariate analysis for BP 24-hour, daytime and night-
time. Patients ≥ 65 years only had significant result for diastolic nocturnal dip and SD of the night-time 
SBP. 
6.2.4 “How far and how much ABPM data change from before through after the event?”  
From our cohort, 46 patients had ABPM before the first event, but in three, there were not enough 
values to compare. 
We compared the ABPM from 43 patients, from before the first event and after the first event.  
The mean follow-up between first ABPM and the first event was 6.5 ± 4.6 years, and the mean follow 
up between the first event and the second ABPM was 2.7 ± 2.0 years.  
These 43 patients had a lower mean age than the total cohort (61.9 ± 9.7 versus 65.9 ± 10.4), a lower 
proportion of men (60.5% versus 72.6%), lower proportion of diabetics (34.9% versus 37.6%), of 
patients with smoking habits (5.7% versus 19.2%) and a lower use of statins (74.4% versus 91.4%).  
Overall, 21 had coronary event and 22 had stroke as first event. 
ABPM paired variables comparison are presented in Table 25. 
Table 25 - Comparison between ABPM before first event and ABPM after first event 
  n 1st ABPM 2nd ABPM 
Paired samples 
test 
   Mean ± SD Mean ± SD Wilcoxon 
Office SBP (mmHg) 42 161.4 ± 24.4 144.8 ± 24.8 0.002 
Office DBP (mmHg) 42 100.5 ± 13.2 87.2 ± 16.4 0.001 
24 h SBP (mmHg) 43 138.7 ± 16.3 131.7 ± 14.1 0.008 
24 h DBP (mmHg) 43 84.2 ± 10.3 76.7 ± 10.2 0.002 
24 h PP (mmHg) 39 54.2 ± 13.5 53.9 ± 12.0 0.896 
24 h HR (bpm) 43 71.3 ± 7.8 69.6 ± 11.0 0.267 
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  n 1st ABPM 2nd ABPM 
Paired samples 
test 
24 h SD SBP 43 15.9 ± 3.6 14.9 ± 3.9 0.111 
Daytime SBP (mmHg) 43 143.4 ± 16.4 139.3 ± 14.4 0.009 
Daytime DBP (mmHg) 43 88.4 ± 10.4 80.8 ± 10.8 0.003 
Daytime PP (mmHg) 39 54.9 ± 13.9 54.3 ± 11.7 0.816 
Daytime HR (bpm) 43 74.1 ± 8.9 72.4 ± 11.7 0.216 
Daytime SD SBP 43 14.2 ± 3.8 13.5 ± 4.2 0.398 
Night-Time SBP (mmHg) 43 127.7 ± 17.2 123.4 ± 16.6 0.122 
Night-Time DBP (mmHg) 43 74.9 ± 10.6 69.5 ± 10.8 0.010 
Night-Time PP (mmHg) 39 52.6 ± 13.2 53.1 ± 13.5 0.982 
Night-Time SD SBP 43 13.3 ± 3.9 12.2 ± 3.5 0.378 
Morning surge SBP (%) 28 24.3 ± 17.5 20.1 ± 19.7 0.502 
Night-time/daytime SBP 
(%) 
40 10.4 ± 7.2 11.1 ± 15.7 0.536 
Night-time/daytime DBP 
(%) 
37 14.6 ± 9.0 14.8 ± 8.1 0.789 
ABPM – ambulatory blood pressure monitoring; DBP – diastolic blood pressure; HR – heart rate; PP – pulse pressure; SBP – systolic blood 
pressure; SD – standard deviation 
Comparing both ABPM, 24-hour SBP and DBP, daytime SBP and DBP, and night-time DBP had 
significant differences. The mean values in the ABPM before the event are higher than the ABPM after 
the event.  
We further evaluated differences between paired ABPM in the coronary event patients (Table 26) and 
cerebrovascular patients (Table 27). There were 21 patients with first event as coronary and 22 
patients with first event as cerebrovascular. 
Table 26 - Comparison between paired ABPM (before and after the event) - coronary disease patients 
Coronary disease 1st ABPM 2nd ABPM Paired Samples Test 
 Mean ± SD Mean ± SD Wilcoxon 
Office SBP (mmHg) 160.1 ± 24.1 145.4 ± 21.1 0.067 
Office DBP (mmHg) 100.3 ± 13.7 87.1 ± 18.5 0.033 
24 h SBP (mmHg) 136.6  ±  17.7 129.2 ± 10.4 0.032 
24 h DBP (mmHg) 83.0 ±11.6 73.7  ± 7.8 0.023 
24 h PP (mmHg) 54.6  ± 12.4 54.8  ± 12.8 0.906 
24 h HR (bpm) 68.2 ± 5.2 67.3  ± 9.6 0.732 
24 h SD SBP (mmHg) 16.1 ± 2.9 14.8  ± 3.3 0.079 
Daytime SBP (mmHg) 142.2 ± 17.8 134.4 ± 9.9 0.020 
Daytime DBP (mmHg) 87.9 ± 11.4 78.3 ± 9.4 0.038 
Daytime PP (mmHg) 55.4 ± 12.5 55.2 ± 12.0 0.868 
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Coronary disease 1st ABPM 2nd ABPM Paired Samples Test 
Daytime  HR (bpm) 71.1 ± 5.9 70.0 ± 10.5 0.668 
Daytime SD SBP (mmHg) 13.6 ± 2.5 13.2 ± 2.7 0.768 
Night-time SBP (mmHg) 123.3 ± 18.1 119.4 ± 15.4 0.254 
Night-time DBP (mmHg) 71.7 ± 10.7 65.1 ± 7.1  0.040 
Night-time PP (mmHg) 52.7 ± 13.5 53.8 ± 15.6 0.836 
Night-time HR (bpm) 62.2 ± 4.1 62.6 ± 8.4 0.717 
Night-time SD SBP (mmHg) 13.9 ± 5.0 11.9 ± 3.4 0.259 
Morning surge SBP (%) 25.6 ± 10.8 26.3 ± 9.4 0.650 
Night-time/daytime SBP (%) 12.6 ± 6.7 11.4 ± 8.9 0.557 
Night-time/daytime DBP (%) 17.3 ± 7.0 16.8 ± 8.2 0.687 
ABPM – ambulatory blood pressure monitoring; DBP – diastolic blood pressure; HR – heart rate; PP – pulse pressure; SBP – systolic blood 
pressure; SD – standard deviation 
 
Table 27 - Comparison between paired ABPM (before and after the event) - cerebrovascular disease patients 
Cerebrovascular disease 1ste ABPM 2nd ABPM Paired Samples Test 
 Mean ± SD Mean ± SD Wilcoxon 
Office SBP (mmHg) 162.7 ± 25.1 144.2 ± 6.2 0.014 
Office DBP (mmHg) 100.6 ± 13.0 87.4 ± 3.2 0.005 
24 h SBP (mmHg) 140.7 ± 15.0 134.0 ± 3.6 0.055 
24 h DBP (mmHg) 85.4  ± 9.0 79.7 ±  2.5 0.027 
24 h PP (mmHg) 53.9  ± 14.8 53.1 ±  2.5 0.903 
24 h HR (bpm) 74.1  ± 8.8 71.7 ±  2.6 0.269 
24 h SD SBP (mmHg) 15.7 ± 4.2 15.0 ± 1.0 0.570 
Daytime SBP (mmHg) 144.6 ± 15.4 138.1 ± 3.8 0.057 
Daytime DBP (mmHg) 88.9 ± 9.7 83.2 ± 2.5 0.029 
Daytime PP (mmHg) 54.4 ± 15.3 53.5 ± 2.6 0.767 
Daytime HR (bpm) 77.0 ± 10.3 74.6 ± 2.7 0.178 
Daytime SD SBP (mmHg) 14.7 ± 4.8 13.8 ± 1.1 0.426 
Night-time SBP (mmHg) 131.9 ± 15.5 127.1 ± 3.7 0.338 
Night-time DBP (mmHg) 77.9 ± 9.8 73.6 ± 2.6  0.150 
Night-time PP (mmHg) 52.6 ± 13.2 52.4 ± 2.6 0.848 
Night-time HR (bpm) 69.0 ± 8.7 66.3 ± 2.7 0.385 
Night-time SD SBP (mmHg) 12.7 ± 2.4 12.5 ± 0.8 0.910 
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Cerebrovascular disease 1ste ABPM 2nd ABPM Paired Samples Test 
Morning surge SBP (%) 23.3 ± 22.1 14.7 ± 6.4 0.281 
Night-time/daytime SBP (%) 8.6 ± 7.2 10.8 ± 4.2 0.910 
Night-time/daytime DBP (%) 11.9 ± 10.0 12.9 ± 1.8 0.573 
ABPM – ambulatory blood pressure monitoring; DBP – diastolic blood pressure; HR – heart rate; PP – pulse pressure; SBP – systolic blood 
pressure; SD – standard deviation 
 
Overall there is a decrease in the mean values of ABPM. Significant differences are systolic and 
diastolic 24 hour and daytime BP in coronary, but only diastolic reached significance in cerebrovascular 
patients. 
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7 Discussion 
The baseline characteristics of our population are similar to other populations of studies in secondary 
prediction (22)(4). The follow up has a wide range of dispersion (SD of 5.2 years, range 0.0-24.3 years), 
since we did not apply any criteria of timing between ABPM and event. The purpose was to study 
patients of daily real clinical practice and not a chosen population with several exclusion criteria and 
highly specific features.  
Comparing the groups with and without recurrent event, there was no statistical difference 
concerning, age, gender, BMI, dyslipidaemia, diabetes or smoking. One reason for this lack of 
differentiation is that they all are high-risk patients, with established CV disease.  
The population selected had a high preponderance of CV risk factors at baseline. Patients with atrial 
fibrillation were also included, given that some published studies comparing patients with and without 
atrial fibrillation did not find significant difference in both ABPM and office BP (218) suggesting that 
accuracy of ABPM is preserved in these patients. In addition, from the recent European ABPM 
guidelines there is no reason to exclude these patients from evaluation by ABPM in atrial fibrillation 
patients (126). Atrial fibrillation is associated with prevalence of CV disease (219). Atrial fibrillation 
was significantly more common in the recurrent event group, along with the use of anticoagulants. 
The use of anti-coagulants in the group of patients with atrial fibrillation and no recurrent event (74.2% 
of these were under anticoagulants) was higher than in atrial fibrillation group with event, which is 
likely to result in a more efficient protection to these patients. However, the atrial fibrillation 
prevalence increasing with age (220), could explain that in our study it occurred more often in older 
patients (≥ 65 years, see Table 23).  
There was no difference on the use of ACE inhibitors or ARBs, statins or diuretics between the 
recurrent event group and the non-recurrent event. The use of anti-platelets was significantly higher 
in the non-recurrent event group (Table 13). Such effect may be attributed to the well-known 
protection of aspirin in secondary prevention of CV outcome. This difference was not seen when we 
divided the population by age. The patients that had a first coronary event (Table 17) kept the 
difference.  
In our study, the baseline population had a higher proportion of coronary first events than 
cerebrovascular one. However, regarding recurrent events, stroke had higher prevalence than 
coronary events (49 versus 38). It is known that any CV event (coronary or stroke) potentiates the 
occurrence of a new CV event. In Portugal, however, the prevalence of stroke is higher than coronary 
events and the rule of probability may elicit an increase of stroke as a second event after a coronary 
one, given that globally the risk of stroke for the Portuguese population is higher.  
7.1 Does ABPM have any predictive value for recurrent cardiovascular 
disease? Which ABPM variables have higher predictive value for 
recurrent cardiovascular events, if any? 
In our population, daytime SBP significantly predicted total CV events independently from casual BP 
and other confounding factors and it was the most significant and consistent variable associated with 
increased risk of total CV events (see Table 15). Such a prediction persisted when analysed by its SD 
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increments and 10 mmHg increments (see Table 16). Daytime DBP showed significant predictive value 
for recurrent event when adjusted for office DBP and other confounding factors when evaluated as a 
continuous variable and by SD increment, only loosing significance when analysed by 10 mmHg. 
Nonetheless, daytime BP is most significant than night-time. Such data suggest that daytime SBP and 
DBP are the most significant variables for prediction of recurrent CV events.   
In our study 24-hour SBP and 24-hour DBP are both associated with increased risk but less strongly 
than daytime SBP and DBP (see Table 15 and Table 16). Daytime SBP association with risk persisted 
through several adjustments to other variables, which did not happen with 24-h SBP and 24-hour DBP. 
Night-time SBP and DBP were not associated with increased risk in our population of patients with 
previous CV event. Since in the univariate analysis (see Table 14), night/day ratios and morning surge 
were not associated with risk, we did not further evaluate these with the multivariate analysis. 
Night-time BP has been shown to have the highest predictive value in relation to the first CV events 
(7). We may speculate that any CV event introduces changes in the autonomic regulation of the 
circadian BP rhythm that prevent the normal manifestation the night-time BP load. Also, we cannot 
exclude that any more aggressive therapy introduced after the event may change the spontaneous 
feature of night-time BP. 
To our knowledge, there are just few studies that evaluated the predictive value of ABPM for recurrent 
events. Fagard et al (143) performed a meta-analysis of 302 patients with established CV disease, and 
night-time BP was the most significant for risk prediction of CV mortality and major CV events. Night-
day ratio was also predictive of outcome, which was not the case in our sample. Our population has 
higher prevalence of men, smoking and diabetes. Also, our sample has lower mean values of BP (for 
example 134 versus 144 mmHg for daytime SBP, 121 versus 133 mm for night-time SBP, respectively) 
which could influence the results. In other studies in patients with stroke, higher 24-hour SBP (207) 
and higher 24 hour SBP and DBP (210) have been associated with worst outcomes. So, the lower BP 
values of our population may reduce the power of night-time BP to predict recurrent events. Some 
studies evaluated patients with CV event by using ABPM few weeks after the event, what could also 
influence the results (209)(210)(216) and explained the differences versus our study. 
In our cohort, the evaluation of patients with coronary event as a first event (see Table 17 and Table 
18) showed significant risk of a second event associated with daytime SBP, and daytime and night-
time pulse pressure. The group with recurrent event had higher values of all BP variables throughout 
24 hours. A study  which evaluated patients with ABPM three weeks after recent myocardial infarction 
found associated risk with lower levels of mean 24-hour DBP (216). In our subgroup, this was not 
found. The timing of performance of ABPM within 3 weeks of event may have changes related to acute 
changes that had not yet stabilized. 
The evaluation of our subgroup of patients with cerebrovascular events (see Table 19 and Table 20), 
unlike other studies (207)(208)(209), did not show any association with risk  of any ABPM variables. In 
other studies, independent risk has been associated with 24-hour SBP (6)(207) and non-dipping 
pattern associated with risk of stroke in stroke survivors (208). In patients with lacunar stroke, 24-
hour, daytime and night-time SBP and DBP have been associated with risk of microbleeds (209), and 
24-hour SBP and DBP, night-time BP and lower night-time/day ratio were associated with silent 
ischemic cerebral lesions and stroke (210). In our cohort we failed to reproduce these published 
positive significant relations. The fact that our population had a better level of BP control of that found 
in these studies may contribute to explain such differences between studies. 
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7.2 Will the limits of BP that best predict the first CV events be identical to 
those that predict the second events? 
A growing part of the general population has survived a CV event, and the control of risk factors is 
then mandatory. Most recent international guidelines of arterial hypertension recommend lower BP 
below 130/80 mmHg to patients with coronary artery disease (126)(177)(221). The European 
guidelines also recommend this threshold to patients with lacunar stroke patients, preserving that the 
correct BP target is not certain (126). The implied measurement technique for these thresholds is 
office BP.  
The number of studies in secondary prediction concerning the better BP threshold of risk with 24-hour 
BP measurement is scarce. The role of out-of-office BP in the improvement of risk stratification is still 
not well established, as well as the accuracy of the out-of-office BP treatment thresholds (126). This 
is more evident if we are referring to patients with previous CV event.  
We hypothesized that the ABPM thresholds of event risk for patients with CV disease may be different 
from the limits of diagnosis established for patients without previous event.  
In Portugal, CV diseases are the first cause of death and cerebrovascular disease has a much higher 
prevalence and mortality rate than cardiac ischemic disease (164). 
In our study, the baseline population had a higher proportion of coronary first events than 
cerebrovascular (see Table 13). Regarding recurrent events, stroke had higher prevalence than 
coronary events (49 versus 38). Comparing the patients with and without recurrent event, there was 
no statistical difference in terms of age, gender, BMI, diabetes, dyslipidaemia or smoking. This could 
be explained by the fact that they all are high-risk patients, with previous CV event. In fact, all the 
population had high preponderance of CV risk factors at baseline including dyslipidaemia, which 
affected 85% of the patients without recurrent event and 70% of the patients with event recurrence. 
Also, treatment with angiotensin converting enzyme inhibitors or angiotensin receptor blockers, 
statins, diuretics and anti-platelets showed no difference in prevalence between the two groups. So, 
all patients were heavily treated and with high CV risk at baseline. 
Considering ABPM variables, SBP was significantly higher in patients with second event when 
comparing to the ones without second event, whether for 24-hour, daytime or night-time SBP. DBP 
had also significant differences between these populations, being higher in those with recurrent 
event. It is expected that higher burden of cardiovascular disease, namely higher blood pressure, 
would be associated with higher probability of event.  
The International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome 
(IDACO) evaluated 5682 patients without established CV disease for 9.7 years (222) and determined 
ABPM thresholds which corresponded to the 10-year CV risks associated with BP thresholds in 
guidelines of arterial hypertension. The ABPM corresponding limits for hypertension were 131.0 / 79.4 
mmHg for 24-hour, 138.2 / 86.4 mmHg for daytime and 118.5 / 70.8 mmHg for night-time (222). The 
optimal ABP values for 24-hour, daytime and night-time were respectively 116.8 / 64.2 mmHg, 121.6 
/ 78.9 mmHg and 100.9 / 65.3 mmHg; for normal ABP were 123.9 / 76.8 mmHg, 129.9 / 82.6 mmHg 
and 110.2 / 68.1 mmHg. Authors concluded that the best threshold for optimal and normal BP was 
lower than the ones recommended by hypertension guidelines. The 2013 European Position Paper on 
ABPM raises the question whether the current thresholds apply to all ages and conditions (168). 
In our cohort, the univariate cox regression analysis (Table 14), SBP was associated with increased CV 
risk.  The tertiles analysis (Table 21) showed a clear increase in risk with increasing SBP. However, DBP 
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showed a tendency for increased risk with lower values (HR of 0.833 for 24 h-DBP ≥ 78 mmHg 
comparing to 24 h DBP ≤ 67 mmHg; similar results in daytime DBP and night-time DBP) (see Table 21). 
This result was not significant, but low DBP has been associated with increased CV risk (223) in other 
studies, namely because coronary perfusion depends on DBP, and this could be an explanation for this 
tendency. 
In our cohort, the better threshold for prediction of increased recurrent event risk is lower than the 
current guidelines limits. For 24-hour SBP the value was 125 mmHg, for daytime SBP was 131 mmHg 
and for night-time SBP was 112 mmHg. The Kaplan Meier survival curves (see The survival curve of 
patients divided by mean 24-hour SBP < 130 mmHg and ≥ 130 mmHg, daytime < 135 mmHg and ≥ 135 
mmHg and night-time < 120 mmHg and ≥ 120 mmHg, had respectively log-ranks of 0.093, 0.138 and 
0.411. The survival curves using the thresholds of 125 mmHg for 24-hour SBP and 131 mmHg for 
daytime SBP showed a log-rank of 0.004 and 0.007, respectively. 
Figure 4) showed a significant increase in years free of event for patients with mean 24-hour SBP < 
125 mmHg. The survival curve using the threshold of the guidelines (130 mmHg) was not significant. 
The daytime SBP showed the same difference in the survival curves (131 mmHg versus 135 mmHg). 
Night-time survival curve did not show statistical significance both with the 120 or 112 mmHg values. 
This suggests that there is a better cut-off for prediction of risk at lower levels of BP than the ones 
established for treatment. The multivariate Cox regression (Table 22) also presented a significant 
increase for CV events with the thresholds of 125 and 131 mmHg, in comparison with 130mmHg and 
135 mmHg (24-hour SBP and daytime SBP, respectively). In patients with previous CV event heavily 
treated and highly controlled, a significant prediction of risk may be attainable at lower values. Also, 
a decay in the general conditions, associated a multiple risk factors and high burden of disease, could 
influence a decrease in BP. 
Several studies have found a decrease of CV events with the lowering of BP below the established 
thresholds (224)(128). Recent European hypertension guidelines have decreased the threshold for 
treatment for patients with previous stroke or ischemic heart disease (126). A recent meta-analysis 
concerning 26863 patients with very high-risk by symptomatic CV disease found benefit in reducing 
BP even in the normotensive individuals (225). This was found mainly by stroke reduction, 
independently of the drug class used. In populations with high prevalence and mortality by stroke, this 
could indicate a possible change in BP limits for starting medication. To the best of our knowledge, 
there is no prior study with ABPM in patients with previous CV events evaluating the best cut-off for 
risk prediction. Our findings are in line with published studies using office BP.  
Finally, low DBP (<70 mmHg) has been associated with higher CV event risk (226)(227), particularly for 
patients with coronary heart disease (223). However, stroke does not seem to increase with low DBP 
(228)(229). This points for different levels of target organ by low DBP, or to different mechanisms and 
higher cerebroprotection towards low BP (224). Some argue that lower BP targets than the ones 
established currently could not be of benefit for all patients of high risk, except perhaps for 
populations at high risk, with a high prevalence of stroke (230). 
7.3 ABPM prediction values for recurrent cardiovascular events are they 
different between distinct age groups?  
Several features associated with age may enable differences in BP regulation. Younger people are 
more physically active than older patients (231) and changes in the circadian pattern are important in 
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elderly (232) Some studies have addressed changes in ABPM values in different ages (231) and in the 
elderly (232). We evaluated if ABPM predictive value is different according to age. The choice of the 
cut-off value was driven by the value of median (65 years) of our sample. It is also the value for which 
the World Health Organization marks the threshold of the old age. 
In our population, the patients under 65 years had higher prevalence of CV risk factors than the older 
patients: male gender (79.9% versus 66.5%), BMI (28.9% versus 27.8%) and smoking (27.9% versus 
11.8%). Use of statins (78.2% versus 90.1%), dyslipidaemia (74.3% versus 87.3%) and atrial fibrillation 
(6.7% versus 15.5%) had a significant higher prevalence in the older group (see Table 23). The group < 
65 years old had a higher 24 hours, daytime and night-time DBP and a smaller pulse pressure when 
compared to the group ≥ 65 years old. DBP usually increases with aging until the fifth decade and 
starts to decay from the sixth decade forward until at least 84 years old (233). 
We used univariate and multivariate Cox regression to evaluate the possible risk of total CV events. 
Table 24 shows the HR of the relationship between ABPM variables and outcome. In the group < 65 
years, the 24-hour, daytime and night-time SBP and DBP were significantly associated with risk of CV 
events, in multiple adjusted model. The differences in comorbidities between the groups could have 
an influence in these results, although the multivariate analysis was adjusted for several of them. Also, 
there was a difference in mean DBP value between them, but more importantly the mean BP values 
of the patients < 65 years with recurrent event were significantly higher than those with no recurrent 
event. In the group of patients ≥ 65 years, there was no significant difference between the BP values 
of those with and without event. The higher values of BP in the younger patients could provide a 
higher CV risk for recurrent event, and this could also influence our results. Since age is one of the 
most powerful risk factors which increases known CV risk scores (19)(20), this could lead to a 
devaluating of risk in the younger patients, and by addition a decreasing in intensive therapy.  
In the group ≥ 65 years, diastolic night-time/day ratio was significantly associated with higher risk (see 
Table 24). Although systolic night-time/day ratio hazard ratio was also high, it did not reached 
statistically significance. The median diastolic night-time/day ratio of the elderly group was of 13.0 
mmHg (see Table 24) and  was associated with higher CV risk (176). Although the value of the group < 
65 years old is also high (12.7 mmHg), older people are much more susceptible to high BP dipping, 
increasing risk (234), as described previously. 
7.4 How far and how much does ABPM data change at before and after the 
event?  
In our cohort, 43 patients had ABPM from before and after the event. We performed the comparison 
between paired ABPM to address possible changes over time.  
 These 43 patients had a lower median age than the total cohort (61.9 ± 9.7 versus 65.9 ± 10.4), a 
lower proportion of men (60.5% versus 72.6%), lower proportion of diabetics (34.9% versus 37.6%), 
of patients with smoking habits (5.7% versus 19.2%) and a lower use of statins (74.4% versus 91.4%). 
The mean follow-up between first ABPM and the first event was 6.5 ± 4.6 years, and the mean follow 
up between the first event and the second ABPM was 2.7 ± 2.0 years. 
The comparison of 43 paired ABPM between before and after the event showed a significant decrease 
of BP mean values in the ABPM after the first event (see Table 25): 24-hour SBP and DBP, daytime SBP 
and DBP, and night-time DBP. This could be explained by a better risk control after the event with an 
increase in therapy leading to a better control of BP. 
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From this subgroup, we further analysed the patients with coronary events and with stroke. In the 
patients with coronary events, there was a significant decrease in 24-hour SBP and DBP, daytime SBP 
and DBP, night-time DBP. Intensive therapy after the event and control of risk factors may be the main 
reasons for these changes. In the stroke patients, only 24-hour DBP and daytime DBP decreased 
significantly.  
To the best of our knowledge, this is the first Portuguese study that evaluated paired ABPM from 
before and after a CV event. We observed a decrease in all variables, which could be a consequence 
of more rigorous therapy from event, a higher adherence to therapy. Also, reverse causality should be 
bear in mind in patients with high burden of disease. Older age, end organ damage like heart failure 
or general frailty could be part of an overall poor health status, in which low systolic or diastolic blood 
pressure may be a consequence of the disease and not the cause (235). 
There are limitations to this study. This study evaluated patients of daily clinical practice. The purpose 
was to study patients of daily real clinical practice and not a chosen population with several exclusion 
criteria and highly specific features. This implies a poor control over several conditions that interfere 
in the results. It is an observational study, with lack of control of several confounders, including 
comorbidities through follow-up. Management of medication through follow-up was not considered 
and it could interfere with outcome. The ABPM date in relation to first event is not homogeneous 
among our population, adding to the problem of ABPM reproducibility.  The limited number of 
recurrent strokes (in patients with previous stroke) prevented further analysis.  
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8 Conclusion 
8.1 Overall conclusions 
Just a few published studies evaluated the predictive value of ABPM for the occurrence of CV events 
after a previous event. Our study aimed at bringing new contributions to the field. 
- We found that ABPM clearly have a strong predictive value for recurrent CV disease and that 
among all ABPM data, the daytime SBP and daytime DBP had the highest predictive value for 
recurrent CV events. In our population with well controlled BP and heavily treated, daytime BP 
may become more relevant and less modifiable by other influences on circadian control of BP.   
- We found that the ABPM limits that predict the second events are much lower than those 
predicting first events which may be related with more aggressive treatments and more 
vulnerable general conditions. 
- We found that ABPM has a stronger prediction value for recurrent CV events in patients < 65 old 
when comparing to patients ≥ 65 years old. This predictive value is associated to 24-hour systolic 
and diastolic BP and to pulse pressure.  In our population of high-risk, higher prevalence of 
comorbidities and less intensity of treatment in younger patients with previous event may be 
related to higher values of BP and increased ABPM predictive value. 
- We found that the main changes in ABPM from before to after the event, in our population, was 
a decrease in BP values globally. This decrease was more evident in coronary patients than in 
stroke patients. Increased therapy and control of risk factors may have a huge influence in these 
results.   
8.2 Future directions 
The work we present here is a modest contribution to address the existing research gap with respect 
to the role of ABPM-related variables in the prediction of cardiovascular events in the long-term, for 
patients that already suffered from a previous event.  
Although our findings offer relevant insights for the Portuguese population, the work is certainly not 
concluded. The research will benefit from a larger sample population and addition control of 
confounding factors. The number of patients in each event group would need to increase to 
understand whether the ABPM alterations are caused by a type of event or concerns the entire 
cardiovascular spectrum. 
It was our believing, at the beginning of the thesis project, that the field requires additional research; 
after this work, our conviction is even stronger. We heartily support the need for randomized, 
prospective studies with sound methodological approaches to further investigate the promising role 
of ABPM in secondary event prediction. 
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